**MANAGEMENT OF DIABETES AND HYPERGLYCEMIA IN HOSPITALIZED PATIENTS**

**Ketan Dhatariya**, **MBBS, MSc, MD, MS, FRCP, PhD**. Norfolk and Norwich University Hospitals, Colney Lane, Norwich, UK. ketan.dhatariya@nnuh.nhs.uk

**Guillermo E. Umpierrez**, **MD, CDE, FACE, MACP**. Emory University School of Medicine. Atlanta, Georgia, U.S.A. GEUMPIE@emory.edu

**Updated October 18, 2024**

**ABSTRACT**

Diabetes is the most prevalent metabolic disorder, and in 2021, the International Diabetes Federation estimated that it affected 537 million adults globally. In 2024, the United States Centers for Disease Control reported that 38.1 million adult Americans, or 14.7% of the adult population, have diabetes. Patients with diabetes have a 3-4-fold greater chance of hospitalization compared to those without diabetes. In 2020, in the U.S., there were over 7.86 million hospital discharges for adults listed as having diabetes. Hyperglycemia, defined as a blood glucose greater than 140 mg/dl (7.8 mmol/l), is reported in 22-46% of non-critically ill hospitalized patients. Extensive data indicates that inpatient hyperglycemia, in patients with or without a prior diagnosis of diabetes, is associated with an increased risk of complications and mortality. In 2025, the American Diabetes Association (ADA) recommends that once therapy is initiated, a glycemic goal of 140–180 mg/dL (7.8–10.0 mmol/L) is recommended for most critically ill (ICU) individuals with hyperglycemia. More stringent individualized glycemic goals may be appropriate for selected critically ill individuals if they are achieved without significant hypoglycemia. However, for non-critically ill (non-ICU) individuals, a glycemic goal of 100-180 mg/dL (5.6-10.0 mmol/L) is recommended, if achieved without significant hypoglycemia. Insulin remains the best way to control hyperglycemia in the inpatient setting, especially in critically ill patients. Intravenously administered insulin is the preferred method to achieve the recommended glycemic target in the ICU. In 2025, the ADA changed its recommendations on using SGLT2 inhibitors in inpatients. They now suggest that in people with type 2 diabetes and heart failure, SGLT2 inhibitors may be started or continued if there are no contraindications (which include prolonged fasting or post-operative recovery). The use of GLP-1 receptor agonists was not recommended in previous guidelines because of the need for more safety and efficacy studies in the inpatient setting. However, increasing evidence indicates that treatment with oral agents such as DPP4 inhibitors, alone or combined with basal insulin, is safe and effective in general medicine and surgery patients with mild to moderate hyperglycemia.

# INTRODUCTION

# Diabetes is the most prevalent metabolic disorder, affecting more than 537 million adults globally and is projected to rise to almost 800 million (10.9% of the adult population) by 2045 (1). In the United States, data from the National Diabetes Statistics Report in 2023 estimated that 38.4 million people of all ages or 14.7% of all U.S. adults had diabetes (2). The percentage of the population with diagnosed diabetes is expected to rise, with one study projecting that as many as one in three U.S. adults will have diabetes during their lifetime (3). People with diabetes have a 35% greater chance of referral for elective operations and a 3-4-fold greater chance of hospitalization compared to those without diabetes (4-7). Data from the US and Scotland estimate that of those individuals with a discharge diagnosis of diabetes, 30% will require two or more hospitalizations in any given year (5; 6; 8). In 2020, in the U.S., there were over 7.86 million hospital discharges for adults listed as having diabetes, (i.e., diabetes as either a principal diagnosis for hospitalization or as a secondary diagnosis, coexisting condition) (9). Data from the USA suggest that the prevalence of diabetes in the adult inpatient population has increased by 2.5% annually from 17.1% to 27.3% between 2000 and 2018 (10). In the UK, the annual National Diabetes Inpatient Audit suggested that the prevalence of diabetes amongst inpatients had risen from 15% in 2010 to almost 20% in 2019 (11). In addition, those hospitalized with a diagnosis of diabetes stay in the hospital for longer than those without a diagnosis of diabetes admitted for the same condition (12; 13).

Diabetes was the 8th leading cause of death in the United States in 2021, accounting for 31.1 deaths per 100,000 of the population (2). A further 120.3 per 100,000 people had diabetes listed as a contributing factor towards the cause of death (2). Not only does diabetes have a significant economic impact on those living with the condition, but it also imposes a substantial burden on the economy, with a total estimated cost of treating people diagnosed with diabetes in the United States in 2022 of $413 billion – or 25% of all health care spending in the US (14). This included $306.6 billion in direct medical costs. It is estimated that a further cost of $96.5 billion is incurred due to reduced productivity (14). Data from Ireland estimated that the overall cost of treating diabetes represented between 12 and 14% of the annual health budget. The cost per admission for someone with type 1 or type 2 diabetes was €4,027 and €5,026, respectively (15). Globally, diabetes care costs have been estimated at $1.3 trillion, rising to an estimated $2.1-2.5 trillion by 2030 (16; 17). This represents a rise in spending on diabetes as a proportion of global gross domestic product from 1.8% in 2015 to 2.2% in 2030 (17). Other than the costs of diabetes medications, the most significant component of this medical expenditure is hospital inpatient care (13; 18).

Hyperglycemia is defined as a blood glucose concentration greater than 140 mg/dl (7.8 mmol/l) (19-21). It is not just found in those with a pre-existing diagnosis of diabetes but in those with stress hyperglycemia or previously undiagnosed diabetes. The prevalence has been reported to be 22% to 46% in non-critically ill hospitalized patients (8; 19). Extensive observational and trial data indicate that inpatient hyperglycemia, in patients with or without a prior diagnosis of diabetes, is associated with an increased risk of complications and mortality, a longer hospital stay, a higher admission rate to the intensive care unit (ICU), and a higher need for transitional or nursing home care after hospital discharge (8; 22; 23).

Several studies and meta-analyses have shown that attempting ‘tight’ glycemic control using intensive insulin therapy is associated with an increased risk of hypoglycemia (24-28), which has been associated with increased morbidity and mortality in hospitalized patients (19; 29-34). Thus, while insulin therapy is recommended for managing hyperglycemia in hospitalized patients, the concern about hypoglycemia has led leading professional organizations worldwide to recommend targets that avoid the risk of hypoglycemia (20; 27; 35-38).

This chapter reviews the pathophysiology of hyperglycemia during illness, the mechanisms for increased complications and mortality due to hyperglycemia and hypoglycemia, and the evidence supporting different therapies and approaches for the management of inpatient diabetes and hyperglycemia in critical care, general medicine, and surgical settings.

# PREVALENCE OF DIABETES AND HYPERGLYCEMIA IN THE HOSPITALIZED PATIENT

Observational studies have reported a prevalence of hyperglycemia and diabetes ranging from 38% to 40% in hospitalized patients (8) and in 70-80% of those with diabetes who have a critical illness or cardiac surgery (39-41). A 2017 report using point-of-care bedside glucose tests data in almost 3.5 million people (653,359 ICU and 2,831,436 non-ICU) from 575 hospitals in the United States reported a prevalence of hyperglycemia (defined as a glucose level >180 mg/dl [10.0 mmol/l]) of 32.2% in ICU patients and in 32.0% of non-ICU patients (39). A study of 893 people across 69 ICUs in France reported a prevalence of hyperglycemia (>180 mg/dl [10 mmol/l]) of 45% (42). Other USA data suggest that between 2000 and 2018, the prevalence of diabetes amongst adult inpatients increased by 2.5% per year from 17.1% to 27.3% (10), and that over 33% of all hospital discharges in 2020 had diabetes listed as a diagnosis (9). However, this does not include those individuals who develop stress hyperglycemia. The American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) consensus on inpatient hyperglycemia defined stress hyperglycemia or hospital-related hyperglycemia as any blood glucose concentration >140 mg/dl (>7.8 mmol/l) in patients without a prior history of diabetes (19; 20). The data from the US included those with newly identified diabetes or stress hyperglycemia as well as those with a prior diagnosis of diabetes (39). Although stress hyperglycemia typically resolves as the acute illness or surgical stress abates, a significant proportion (up to 60% in some reports) develop confirmed diabetes at 6-12 months after discharge (43; 44). A guide from the UK on the management of ‘diabetes at the front door’, also recommends that any individual without diabetes who presents acutely unwell should have a capillary glucose measurement and blood/urine ketone measurement taken, but that if it is high on admission (i.e. >140mg/dl [7.8 mmol/l]) and subsequently goes down to normal, then a diagnosis of stress hyperglycemia should be made and documented to the primary care team (21).

Measurement of HbA1c is indicated in people with hyperglycemia without a history of diabetes to differentiate between stress-induced hyperglycemia and previously undiagnosed diabetes (21; 45-48). The ADA also recommends that an HbA1c be done in those with diabetes who have not had it measured in the preceding 3 months (48). The Endocrine Society and the UK Joint British Diabetes Societies for Inpatient Care (JBDS) recommendations indicate that people hospitalized with elevated blood glucose >140 mg/dl (7.8 mmol/l) and an HbA1c of 6.5% (48 mmol/mol) or higher can be identified as having diabetes (19; 21). Given the increasing prevalence of diabetes, the UK has also produced a calculator to help teams work out their optimal staffing levels (49).

# PATHOPHYSIOLOGY OF HYPERGLYCEMIA DURING ILLNESS

In subjects without diabetes during the fasted state, plasma glucose is maintained between 70 – 100 mg/dl (3.9 – 5.6 mmol/l) by a finely regulated balance between glucose production from the liver and kidneys and glucose utilization in peripheral tissues. Maintenance of near-normal glucose concentration is essential for cardiovascular and central nervous system function because the brain can neither synthesize nor store glucose (50; 51).

Systemic glucose balance is maintained by dynamic, minute-to-minute regulation of endogenous glucose production and glucose utilization by peripheral tissues (52). Glucose production is accomplished by gluconeogenesis or glycogenolysis primarily in the liver and, to a lesser degree, by the kidneys (53; 54). Gluconeogenesis results from converting non-carbohydrate precursors such as lactate, alanine, and glycerol to glucose in the liver (55). Excess glucose is polymerized into glycogen, mainly stored in the liver and muscle. Hyperglycemia develops because of three processes: 1) increased gluconeogenesis, 2) accelerated glycogenolysis, and 3) impaired glucose utilization by peripheral tissues (Figure 1).



**Figure 1. Pathogenesis of hyperglycemia. Hyperglycemia results from increased hepatic glucose production and impaired glucose utilization in peripheral tissues. Reduced insulin and excess counter-regulatory hormones (glucagon, cortisol, catecholamines, and growth hormone) increase lipolysis and protein breakdown (proteolysis) and impair glucose uptake by peripheral tissues. Hyperglycemia causes osmotic diuresis, leading to volume depletion, decreasing glomerular filtration rate, and worsening hyperglycemia. At the cellular level, increased blood glucose concentrations result in mitochondrial injury by generating reactive oxygen species and endothelial dysfunction by inhibiting nitric oxide production. Hyperglycemia increases levels of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin [IL]-6, leading to immune system dysfunction. These changes can eventually lead to an increased risk of infection, impaired wound healing, multiple organ failure, prolonged hospital stay, and death. Adapted from ref (25).**

From the quantitative standpoint, inappropriately increased hepatic glucose production represents the major pathogenic disturbance. Increased hepatic glucose production results from the high availability of gluconeogenic precursors. These include the amino acids alanine and glutamine, which result from accelerated proteolysis and decreased protein synthesis; lactate, which results from increased muscle glycogenolysis; glycerol, which results from increased lipolysis; and the increased activity of gluconeogenic enzymes (phosphoenol pyruvate carboxykinase, fructose-1,6-bisphosphatase, and pyruvate carboxylase) (53; 55).

Glucose metabolism is maintained by an interaction of glucoregulatory hormones – insulin and counter-regulatory hormones (glucagon, cortisol, epinephrine, norepinephrine, and growth hormone). Insulin controls hepatic glucose production by suppressing hepatic gluconeogenesis and glycogenolysis. Depending on the concentration in the circulation, insulin inhibits glycogenolysis and protein breakdown and, at higher concentrations, promotes protein anabolism in insulin-sensitive tissues such as muscle, glucose uptake, and glycogen synthesis (52; 56; 57). In addition, insulin is a potent inhibitor of lipolysis, free fatty acid oxidation, and ketogenesis (56-58).

Counter-regulatory hormones also play an essential role in regulating glucose production and utilization. Glucagon is the most important glycogenolytic hormone, and therefore regulates hepatic glucose production in healthy individuals and in every state of hyperglycemia (53). During stress, excess concentration of counter-regulatory hormones results in altered carbohydrate metabolism by inducing insulin resistance, increasing hepatic glucose production, and reducing peripheral glucose utilization. In addition, high epinephrine levels stimulate glucagon secretion and inhibit insulin release by pancreatic β-cells (59; 60).

The development of hyperglycemia results in an inflammatory state characterized by an elevation of pro-inflammatory cytokines and increased oxidative stress markers (61-63). Circulating levels of TNF-α, IL-6, IL1-ß, IL-8, and C-reactive protein are significantly increased two- to fourfold on admission in people with severe hyperglycemia compared with control subjects, and levels returned to normal levels after insulin treatment and resolution of hyperglycemic crises (61). Raised concentrations of TNF-α lead to insulin resistance at the level of the insulin receptor and through altered regulation of the insulin-signaling pathway (62; 64). In addition, preventing insulin-mediated activation of phosphatidylinositol 3- kinase TNF-α reduces insulin-stimulated glucose uptake in peripheral tissues (62; 64; 65).

# CONSEQUENCES OF HYPERGLYCEMIA IN THE HOSPITALIZED PATIENTS

A large body of literature, including observational and prospective randomized clinical trials, in people with and without diabetes, as well as those who are critically or non-critically ill has shown a strong association between hyperglycemia (in particular, a blood glucose >200mg/dl [11.0mmol/l]) and poor clinical outcomes, such as mortality, infections, and hospital complications compared to those with a glucose concentration of <100mg/dl (5.6mmol/l) (5; 66-76). This association correlates with the severity of hyperglycemia prior to or on admission and during the hospital stay (72; 77-79). Of interest, increasing evidence indicates an increased risk of complications and mortality in patients without a history of diabetes (stress-induced) compared to patients with a known diagnosis of diabetes (8; 69; 75; 77; 80; 81). It is not clear if stress hyperglycemia is the direct cause of poor outcomes or if it is a general marker of the severity of illness. However, there are data to show that those without a prior history of diabetes have fewer point-of-care glucose concentrations measured compared to those with diabetes, even when glucose concentrations are just as high (75; 82). In those who had diabetes, having more point-of-care tests increases contact with the ward staff, suggesting that impending complications may be picked up sooner, resulting in lower mortality. These data correlate with other work that also shows that those with lower preoperative HbA1c lower the number of post-operative glucose checks in a general surgical population (83).

The mechanisms implicated in the detrimental effects of hyperglycemia during acute illnesses are not entirely understood. Current evidence indicates that severe hyperglycemia results in impaired neutrophil granulocyte function, high circulating free fatty acids, and overproduction of pro-inflammatory cytokines and reactive oxygen species (ROS) that can result in direct cellular damage and endothelial and immune dysfunction (84; 85).

The majority of evidence linking hyperglycemia and poor outcomes comes from studies in the ICU. Falciglia et al., in a retrospective study of over 250,000 veterans admitted to various ICUs, reported that hyperglycemia is an independent risk factor for mortality and complications (77). In a nonrandomized, prospective study, Furnary et al. followed 3,554 people with diabetes who underwent coronary artery bypass graft. These were treated with either intermittent subcutaneous insulin (SCI) or with a continuous intravenous insulin infusion (CIII). The group treated with SCI achieved an average blood glucose of 214 mg/dl (11.9 mmol/l), compared to 177 mg/dl (9.8 mmol/l) in the CIII group. The CIII group had significantly fewer deep sternal wound infections and a 50% lower risk-adjusted mortality (73; 86). In other ICU studies, patients with blood glucose levels >200 mg/dl (>11.1 mmol/l) were shown to have higher mortality compared to those with blood glucose levels <200 mg/dl (<11.1 mmol/) (72; 75). Importantly however, once again it has been shown that it was those people who were not previously known to have diabetes yet who developed hyperglycemia on the ICU who fared worse (75; 87). This was confirmed by another ICU study looking at almost 350,000 people, looking at the outcomes of those with sepsis (88). These authors showed that having hyperglycemia without a prior diagnosis of diabetes was associated with an increased stay in hospital and ICU and greater 90-day mortality (88). However, there was no difference in outcomes for those with diabetes unless they had experienced severe hypoglycemia (<40 mg/dl [2.2 mmol/l]), in which case mortality rose (OR 2.95 95%CI 1.19-7.32) (88). Another ICU study randomized 9230 people who were not given early parenteral nutrition to liberal glucose control (insulin only started if glucose rose to >215 mg/dl [>11.9 mmol/l]), or tight glucose control with glucose concentrations maintained between 80 and 110 mg/dl (4.4 – 6.1 mmol/l). These authors showed no differences in outcome, including length of time in ICU, infection rates, time on respiratory or hemodynamic support, or mortality. The only differences were lower severe acute kidney injury incidence and cholestatic liver dysfunction in the tight glycemic control arm (89).

The association of hyperglycemia and poor outcomes also applies to those not in ICU but admitted to general medicine, surgery, or mental health services. In such individuals, hyperglycemia is associated with poor hospital outcomes, including prolonged hospital stay, infections, disability after hospital discharge, and death (5; 8; 66; 67; 81; 90). In a study of 1,886 patients admitted to a community hospital, mortality in the general floors was significantly higher in patients with newly diagnosed hyperglycemia and with known diabetes compared to subjects with normal glucose values (10% vs. 1.7% vs. 0.8%, respectively, p < 0.01) (8). In a prospective cohort multicenter study of 2,471 patients with community-acquired pneumonia, those with an admission glucose level of >198 mg/dl (>11.0 mmol/l) had a greater risk of mortality and complications than those with glucose <198 mg/dl (<11.0 mmol/l) (91). The risk of complications increased by 3% for each 18 mg/dl (1.0 mmol/l) increase in admission glucose (91). In a retrospective study of 348 patients with chronic obstructive pulmonary disease and respiratory tract infection, the relative risk of death was 2.1 in those with a blood glucose of 126-160 mg/dl (7.0-8.9 mmol/l), and 3.4 for those with a blood glucose of >162 mg/dl (9.0 mmol/l) compared to patients with a blood glucose of 108 mg/dl (6.0 mmol/l) (92). Similar data from a systematic review and meta-analysis from 38 studies of people who needed hospitalization for community-acquired pneumonia showed that in those without a prior diagnosis of diabetes, hyperglycemia was associated with an almost doubling of the need for ICU admission (crude OR 1.82, 95% CI 1.17 to 2.84) and in-hospital mortality (adjusted OR 1.28, 95% CI 1.09 to 1.50) (81). Those people already known to have diabetes had no increased risk of either.

General surgery patients with hyperglycemia during the perioperative period are also at increased risk for adverse outcomes. Reviews of diabetes and the risk of surgical site infection across a variety of surgical specialties have shown that high peri-operative glucose is associated with an increased risk of infection (93; 94). In a case-control study, elevated preoperative glucose levels increased the risk of postoperative mortality in patients undergoing elective non-cardiac non-vascular surgery (95). Patients with glucose levels of 110-200 mg/dl (5.6-11.1 mmol/l) and those with glucose levels of >200 mg/dl (>11.1 mmol/l) had, respectively, 1.7-fold and 2.1-fold increased mortality compared to those with glucose levels <5.6 mmol/l (<110 mg/dl) (95). In another study, patients with glucose levels >220 mg/dl (>12.2 mmol/l) on the first postoperative day had a rate of infection 2.7 times higher than those who had serum glucose levels <220 mg/dl (<12.2 mmol/l) (96). Other authors showed an increase of postoperative infection rate by 30% for every 40mg/dl (2.2 mmol/l) rise in postoperative glucose level above 110 mg/dl (6.1 mmol/l) (96). Further, a study looking at perioperative glycemic control and the effect on surgical site infections in people with diabetes undergoing foot and ankle surgery showed that 11.9% of those with a serum glucose ≥200 mg/dl (11.1 mmol/l) during the admission developed a surgical site infection versus only 5.2% of those with a serum glucose <200 mg/dl (11.1 mmol/l) (odds ratio = 2.45; 95% CI 1.09-5.52, P = 0.03) (97). Lastly, a prospective randomized study looking at the impact of glycemic control at 1-year post liver transplant showed that in those randomized to glycemic control of blood glucose below 140 mg/dl (7.8 mmol/l), any infection within one year occurred in 35 of the 82 patients (42.7%) versus 54 of 82 (65.9%) in those randomized to glycemic control of 180 mg/dl (10.0 mmol/l) (P = 0.0046) (98).

Emerging evidence suggests that early intervention and the use of technology allowing proactive identification of people at risk help to reduce hospital-acquired infection rates, episodes of hyper- and hypoglycemia, and, in some cases, length of stay (99-102). A meta-analysis also shows that improving peri-operative glycemic control reduced postoperative infection rates (103).

In summary, despite a large amount of work having been done, and the numerous data showing the association – but not causation – between hyperglycemia and poor outcomes, and because there remain a very few robust intervention studies showing a benefit of glycemic control, the optimal blood glucose concentration for people on ICU has yet to be determined (104; 105).

# GLYCEMIC TARGETS IN THE ICU AND NON-ICU SETTINGS

The American Diabetes Association (ADA) and American Association of Clinical Endocrinology (AACE) task force on inpatient glycemic control and other groups recommended differing glycemic targets in the ICU setting (20) (Table 1). These guidelines suggest targeting a BG level between 140 and 180 mg/dl (7.8 and 10.0 mmol/l) for the majority of ICU patients and a lower glucose target between 110 and 140 mg/dl (6.1 and 7.8 mmol/l) in selected ICU patients (i.e., centers with extensive experience and appropriate nursing support, cardiac surgical patients, patients with stable glycemic control without hypoglycemia). Glucose targets >180 mg/dl (>10.0 mmol/l) or <110 mg/dl (<6.1 mmol/l) are not recommended in ICU patients. There is an argument that lowering glucose thresholds for hospital patients will likely be associated with harm (32). Still, an equally persuasive argument suggests that implementing the thresholds advocated by national and organizational guidelines has led to safer care (106).

The Society of Critical Care Medicine (SCCM) guidelines for the management of hyperglycemia in critically ill (ICU) patients recently “recommended against” titrating an insulin infusion to a lower glucose target of 80–139 mg/dL (4.4–7.7 mmol/L) as compared with a higher BG target range of 140–200 mg/dL (7.8–11.1 mmol/L) to reduce the risk of hypoglycemia (107). They also recommended that clinicians should initiate glycemic management protocols and procedures to treat persistent hyperglycemia greater than or equal to 180 mg/dL (10 mmol/L) to maintain target glucose below <180 mg/dl (<10.0 mmol/l) in critically ill adults (107). They also suggest that the insulin regimen and monitoring system be designed to avoid and detect hypoglycemia (blood glucose <70 mg/dl [<3.9 mmol/l]) and to minimize glycemic variability.

|  |
| --- |
| Table 1. Major Guidelines for Treatment of Hyperglycemia in a Hospital Setting |
|  | ICU | Non-ICU |
| ADA/AACE (20; 108)  | Initiate insulin therapy for persistent hyperglycemia (glucose >180 mg/dl [>10 mmol/l]).Treatment goal: For most people, target a glucose level between 140 – 180 mg/dl (7.8 – 10.0 mmol/l].More stringent goals (110 – 140 mg/dl [6.1 – 7.8 mmol/l]) or 100 – 180 mg/dL (5.6 –10.0 mmol/L), may be appropriate for selected patients and are acceptable if they can be achieved without significant hypoglycemia | No specific guidelines.Insulin therapy should be initiated for the treatment of persistent hyperglycemia ≥180 mg/dL (10.0 mmol/L) and targeted to a glucose range of 140 –180 mg/dL (7.8 – 10.0 mmol/L) for most critically ill patients.More stringent goals, such as 110–140 mg/dL (6.1–7.8 mmol/L), may be appropriate for selected patients (e.g., critically ill postsurgical patients or patients with cardiac surgery) as long as they can be achieved without significant hypoglycemia. Less stringent targets (e.g., >250 mg/dL (13.9 mmol/L) may be appropriate in people with severe comorbidities or end of life care. |
| ACP (27) | Recommends against intensive insulin therapy in those with or without diabetes in surgical / medical ICUsTreatment goal: target glucose between 140 – 200 mg/dl (7.8 – 11.0 mmol/l), in people with or without diabetes, in surgical / medical ICUs |  |
| Critical Care Society (107) | BG >180 mg/dl (>10.0 mmol/l) should trigger insulin therapy.Treatment goal: maintain glucose <180 mg/dl (<10.0 mmol/l) for most adults in ICU.Maintain glucose levels <180 mg/dl (10.0 mmol/l) while avoiding hypoglycemia. |  |
| Endocrine Society (19; 109) |  | Pre-meal glucose target <140 mg/dl (<7.8mmol/l) and random blood glucose <180 mg/dl (<10.0 mmol/l). Those with insulin treated diabetes aim for a target glucose of 100 – 180 mg/dL (5.6 – 10 mmol/L). A lower target range may be appropriate in people able to achieve and maintain glycemic control without hypoglycemia. A glucose of <180 – 200 mg/dl (<10.0 – 11.0 mmol/l) is appropriate in those with terminal illness and/or with limited life expectancy or at high risk for hypoglycemia.Adjust antidiabetic therapy when glucose falls <100 mg/dl (<5.6 mmol/l) to avoid hypoglycemia. |
| Society of Thoracic Surgeons (110) | Continuous insulin infusion preferred over SC or intermittent intravenous boluses.Treatment goal: Recommend glucose <180 mg/dl (<10.0 mmol/l) during surgery (≤110 mg/dl [≤6.1 mmol/l] in fasting and pre-meal states) |  |
| Joint British Diabetes Society for Inpatient Care (111) |  | Target blood glucose levels in most people of between 108 – 180 mg/dl (6.0 – 10 mmol/l) with an acceptable range of between 72 – 216 mg/dl (4.0 – 12.0 mmol/l). |

AACE/ADA, American Association of Endocrinologists and American Diabetes Association joint guidelines; ACP, American College of Physicians; ADA, American Diabetes Association; ICU, intensive care unit; SC, subcutaneous.

In the non-ICU setting, the Endocrine Society and the ADA/AACE Practice Guidelines recommended a pre-meal glucose of <140 mg/dl (<7.8 mmol/l) and a random BG of <180 mg/dl (<10.0 mmol/l) for the majority of non-critically ill patients treated with insulin (19; 20; 35; 109). More recently, the American Diabetes Association has recommended that target glucose for most general medicine and surgery patients in non-ICU settings should be between 140 – 180 mg/dl (7.8 – 10.0 mmol/l) (108). In contrast, higher glucose ranges (>200 mg/dl [>11.1 mmol/l]) may be acceptable in people who are terminally ill or in those with severe comorbidities as a way of avoiding symptomatic hyperglycemia (19; 112).

Guidelines from the JBDS in the UK published over the last few years aim for target blood glucose concentrations in most people between 108 – 180 mg/dl (6.0 – 10.0 mmol/l) with an acceptable range of between 72 – 216 mg/dl (4.0 – 12.0 mmol/l) (111). Table 1 summarizes the currently available guidelines for managing hyperglycemia in the hospital setting.

# EVIDENCE FOR CONTROLLING HYPERGLYCEMIA IN ICU AND NON – ICU SETTINGS

In 2001, the Leuven surgical ICU study promoted intensive glycemic control in the critical care setting (113). This study randomized 1,548 people admitted to the surgical ICU (63% cardiac cases, 13% with diabetes, with most receiving early parenteral nutrition). Individuals were randomized to either conventional therapy, with target glucose between 180 – 200 mg/dl (10.0 – 11.1 mmol/l), or intensive treatment to target glucose between 80 – 110 mg/dl (4.4 – 6.1 mmol/l). Those in the conventional arm had a mean daily glucose average of 153 mg/dl (8.5 mmol/l), and those in the intensive arm had an average glucose of 103 mg/dl (5.7 mmol/l). Those in the intensive group had significantly less bacteremia, fewer antibiotic requirements, lower length of ventilator dependency, lower number of ICU days, and an overall 34% reduction in mortality (113). Following a similar study design, the same group of investigators randomized people to a medical ICU (18% with diabetes) and reported that intensive insulin therapy (mean daily glucose of 111 mg/dl [6.2 mmol/l]) resulted in less ICU and total hospital complications in those with three days of insulin treatment (114). These two studies together, based on the positive outcomes on morbidity and mortality, suggested a glycemic target in the ICU of 140 – 180 mg/dl (7.8 – 10.0 mmol/l) (20). There was also a realization that while lower targets may be appropriate for selected individuals, a target of <110 mg/dl (<6.1 mmol/l) was not recommended (20).

Many well-designed randomized controlled trials and meta-analyses have shown that such low glucose targets are difficult to achieve, even in environments with high staff-to-patient ratios, without increasing the risk for severe hypoglycemia (24; 115-117). In addition, these and other studies failed to show improvement in clinical outcomes and have even shown increased mortality risk with intensive glycemic control, targeting glucose concentrations of (80 – 110 mg/dl [4.4 – 6.1 mmol/l]) versus conventional glycemic control (140 – 200 mg/dl [7.8 – 11.0 mmol/l]) (Table 2) (29; 115-118). Most of these studies showed no differences in clinical outcomes between groups but had an increased risk of severe hypoglycemia in the intensively treated arms. One study in ICU patients was the Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation (NICE-SUGAR) trial, which randomized over 6104 subjects to receive either conventional glycemic control to target glucose <180 mg/dl [<10.0 mmol/l]) or intensive glycemic control (target 81 – 108 mg/dl [4.5 – 6.0 mmol/l]). This study also reported no difference in hospital mortality but found increased mortality at 90 days of follow-up (24.9% vs. 27.5%, p=0.02) (24). In a subsequent analysis of the trial, the NICE-SUGAR investigators reported a higher frequency of hypoglycemia in the intensive arm (6.8% vs. 0.5%), and those with hypoglycemia had a ~2-fold increase in mortality compared to patients without hypoglycemia (29). More recently, Gunst et al. recently published the results of a multicenter, randomized trial involving 9230 patients in medical and surgical ICUs (89). 4622 patients were assigned to liberal glucose control, where insulin was initiated only when the blood glucose level was above 215 mg per deciliter (11.9 mmol per liter), and 4608 patients were assigned to tight glucose control, targeting a glucose level between 80 and 110 mg per deciliter. The primary outcome, the duration of time in ICU care, did not differ significantly between the two trial groups. The hazard ratio for earlier discharge alive with tight glucose control was 1.00 with a 95% confidence interval of 0.96 to 1.04. Effective glycemic separation between the groups was observed, with a median absolute difference of -28 mg/dl (-1.6 mmol/l) in daily blood glucose levels. Additionally, the safety outcome, mortality within 90 days after randomization, was 10.1% in the liberal-control group and 10.5% in the tight-control group. The incidence of other secondary outcomes, including severe hypoglycemia, time to discharge alive from the hospital, use of respiratory support, or in-hospital mortality, were no different between intensive and relaxed glycemic targets, except for a trend in lower rates of liver and kidney injury in the tight control group. Umpierrez recently summarized the data on mortality and outcomes of ICU RCTs (119).

Increasing evidence indicates that high pre-admission glycemic control – as measured by HbA1c >8.0% (64mmol/mol) is associated with lower mortality than those with an HbA1c <6.5% (48mmol/mol) (120). Whether this is due to an increased risk of hypoglycemia in the low HbA1c group or an increased frequency of monitoring or bedside vigilance in those with higher glucose or preadmission HbA1c remains unknown (75; 83).

|  |
| --- |
| **Table 2. Clinical Trials of Intensive Glycemic Control in ICU Populations** |
| **Study** | **Setting** | **Population** | **Percentage with diabetes** | **Clinical Outcome** |
| Malmberg, 1994 (121) | CCU | People with diabetes with suspected or confirmed acute MI | 100 | 28% decrease mortality after 1 year |
| Furnary, 1999 (73) | CCU | People with diabetes undergoing CABG | 100 | 65% decrease in deep sternal wound infection rate |
| Van den Berghe, 2001 (113) | Surgical ICU | Mixed, with CABG | 13 | 34% decrease in mortality |
| Furnary, 2003 (86) | CCU | People with diabetes undergoing CABG | 100 | 50% decrease in adjusted mortality rate |
| Krinsley, 2003 (72) | Medical and surgical ICU | Mixed | 22.4 | 27% decrease in mortality |
| Lazar, 2004 (122) | Operating room and ICU | People with diabetes undergoing CABG | 100 | 60% decrease of post - operative atrial fibrillation |
| Van den Berghe, 2006 (114) | Medical ICU | Mixed | 17 | 18% decrease mortality |
| Gandhi, 2007 (123) | Operating Room | Mixed, undergoing cardiac surgery | 19.6 | No difference in mortality; increase in stroke rate in the intensive treatment arm |
| VISEP, 2008 (115) | Medical ICU | Mixed, admitted with sepsis | 30 | No differences in 28-day or 90-day mortality, end-organ failure, length of stay |
| De La Rosa, 2008 (116) | Medical and surgical ICU | Mixed | 12 | No differences in 28-day mortality or infection rate |
| Glucontrol, 2009 (124) | Medical and surgical ICU | Mixed | 18 | No difference in 28-day mortality |
| NICE-SUGAR, 2009/2012 (24; 29) | Medical and surgical ICU | Mixed | 20 | No difference in 90-day mortality |
| Boston Children’s (SPECS), 2012 (125; 126) | Cardiac ICU | Cardiac surgery, people without diabetes | 0 | No differences in 30-day mortality, length of stay, in the cardiac ICU, length of hospital, duration of mechanical ventilation and vasoactive support, or measures of organ failure |
| ChiP, 2014 (127) | Pediatric ICU | Critical illness/injury/major surgery, those without diabetes. | 0 | No difference in 30-day mortality. Increased hypoglycemia in the intensive treated group |
| CGAO–REA, 2014 (128; 129) | Medical ICU | Mixed | 23 | No difference in 90-day mortality. Increased hypoglycemia in the intensive treated group |
| Okabayashi, 2014 (130) | Surgical ICU | Mixed | 25.3 | Decreased surgical site infection in the intensive treated group |
| Umpierrez (GLUCOCABG) 2015 | Surgical ICU | CABG | 50% | No difference in mortality |
| Gunst et alICU | ICU |  | XX | No difference in mortality |

MI, myocardial infarction, ICU – Intensive Care Unit, CABG – Coronary artery bypass graft. Mixed-study enrolled those with and without diabetes.

The GLUCO-CABG trial was a randomized open-label clinical study that included those with and without diabetes undergoing CABG who experienced perioperative hyperglycemia, defined as a BG >140 mg/dl (>7.8 mmol/l) 6069 (70). A total of 302 people between 18 and 80 years of age were randomized to the intensive glycemic control group (target BG 100 – 140 mg/dl [5.6 – 7.8 mmol/l]) or the control group (BG 141 – 180 mg/dl [7.9 – 10.0 mmol/l]) in the ICU. After transitioning from the ICU to the telemetry floor, patients were managed with a single treatment protocol to maintain a glucose target of <140 mg/dl (<7.8 mmol/l) before meals during the hospital stay. The primary outcome included differences between intensive and conservative glucose control on a composite of perioperative complications, including sternal wound infection, bacteremia, respiratory failure, pneumonia, acute kidney injury, major adverse cardiovascular events including acute coronary syndrome, stroke, heart failure, and cardiac arrhythmias (70). The mean BG during the ICU stay was 132±14 mg/dl (7.3±0.8 mmol/l) in the intensive and 152±17 mg/dl (8.4±1.0 mmol/l) in the conservative group. Intensive glucose treatment resulted in a 20% reduction in perioperative complications compared to the conservative group (42% vs. 52%). Of interest, there were no differences in the rate of complications among patients with diabetes treated with intensive or conservative regimens (42% vs. 52%, p=0.08); however, intensive treatment was associated with a significantly lower rate of complications compared to the conservative group in those without diabetes (34% vs. 55%, p=0.008) (70). Hospitalization costs were lower in the intensive group (median [IQR] $36,681 [28,488 – 46,074] vs. $40,913 [31,464 – 56,629], p=0.04), with an average total cost savings of $3,654 per case compared to conservative glucose control (131).

To date, few large studies have been conducted to determine if improved control in those not in ICU may result in reduced morbidity and mortality in general medical and surgical patients – indeed, until recently, for most people in hospital with diabetes while there are observational data to show that dysglycemia is harmful, there were little data to show that improving glycemic control helps (132). A randomized controlled trial from 2011 reported that improved glucose control using a basal-bolus regimen may reduce hospital complications in general surgery patients (71). Improving glucose control with a basal-bolus regimen significantly reduced the frequency of composite complications, including postoperative wound infection, pneumonia, bacteremia, and acute renal and respiratory failure (71). In that study, treatment with basal-bolus insulin reduced average total inpatient costs per day by 14% or $751 compared to treatment with a correction bolus dose insulin alone (133). Another study from Australia has shown that in a randomized study of 1371 surgical inpatients, 680 with even a single glucose value >200 mg/dl (11.1 mmol/l) received early intervention from the diabetes inpatient team (134). This led to reductions in glucose of a modest -5.4 mg/dl (-0.3 mmol/l), which still equated to a 4.6%, statistically significant reduction in hospital-acquired infections compared to those receiving standard care (134).

# HYPOGLYCEMIA

Hypoglycemia is the most common side effect of treatment of all types of diabetes and stress hyperglycemia in the hospital setting. It presents a significant barrier to satisfactory long-term glycemic control. Hypoglycemia results from an imbalance between glucose supply, glucose utilization, and current insulin levels. Hypoglycemia is defined as a lower-than-normal level of blood glucose. Hypoglycemia is defined as any glucose level <70 mg/dl (<3.9 mmol/l) (108; 135) for hospital inpatients. Level 1 hypoglycemia is a glucose concentration of 54 – 70 mg/dL (3.0 – 3.9 mmol/L). Level 2 hypoglycemia is a blood glucose concentration of <54 mg/dL (3.0 mmol/L) (108). Severe hypoglycemia has been defined by many as <40 mg/dl (<2.2 mmol/l) (136), but a newer definition, Level 3 hypoglycemia, is a glucose concentration low enough where the individual requires third-party assistance to aid recovery (108). The UK JBDS guideline suggests that the lower limit of glucose in the inpatient population should be 108 mg/dl (6.0 mmol/l), and that the range between 72 – 108 mg/dl (4.0 – 6.0 mmol/l) be designated ‘looming’ hypoglycemia, to alert ward staff to take action because of the possibility that lower glucose levels may be associated with harm (137). The exception to this is those people on a diet only or those people on an insulin pump / closed loop system who can self-manage their diabetes while in the hospital.

The incidence of severe hypoglycemia in the different trials ranged between 5% and 28%, depending on the intensity of glycemic control in the ICU (138). Rates from subcutaneous insulin trials in non-critically ill patients range from less than 1% to 33% (71; 139; 140). In 2017, the UK National Diabetes Inpatient Audit (NaDIA) data showed that 18% of people with diabetes in hospital experienced one or more hypoglycemic episodes with a blood glucose <72mg/dl (<4.0 mmol/l) – down from 26% in 2011, with 7% (1 in 14) of all inpatients experiencing episodes requiring third party assistance to administer rescue therapy (141). The NaDIA data also showed that those with type 1 diabetes had the highest prevalence, with 25% experiencing a severe hypoglycemic episode (141). Furthermore, 1.3% (1 in 80) of those in hospitals with diabetes required some form of injectable rescue treatment (i.e., IV glucose or IM glucagon), down from 2.1% in 2011 (141). The same data showed that the highest proportion of episodes occurred overnight (28%) between 05:00 and 09.00 AM when snack availability was likely the lowest (140; 141).

Table 3 lists some key factors that predict the likelihood of someone experiencing a hypoglycemic event while hospitalized. These also include older age, greater illness severity, diabetes, and the use of oral glucose-lowering medications and/or insulin (137; 142-145). In-hospital processes of care that contribute to the risk for hypoglycemia include unexpected changes in nutritional intake that are not accompanied by associated changes in the glycemic management regimen. Examples include (but are not limited to) cessation of nutrition for procedures, an adjustment in the amount of nutritional support, interruption of the established routine for glucose monitoring, deviations from the established glucose control protocols, and failure to adjust therapy when glucose is trending down, or steroid therapy is being tapered (137; 146; 147). A common cause of inpatient hypoglycemia is when handwritten insulin prescriptions lead to errors, including misreading, e.g., when ‘U’ is used for units (i.e., 4U becoming 40 units) or confusing the insulin name with the dose (e.g., Humalog Mix25 becoming Humalog 25 units) (148). Electronic prescribing has been associated with a lower rate of prescription errors (141).

However, other factors may also be involved, such as concurrent use of drugs with hypoglycemic agents, e.g., warfarin, quinine, salicylates, fibrates, sulphonamides (including co-trimoxazole), monoamine oxidase inhibitors, NSAIDs, probenecid, somatostatin analogs, or selective serotonin reuptake inhibitors. Secondary causes of inpatient hypoglycemia include loss of counter-regulatory hormone function, e.g., Addison’s disease, growth hormone deficiency, hypothyroidism, or hypopituitarism.

|  |
| --- |
| **Table 3. Common Risk Factors for Developing Hypoglycemia in the Hospital** |
| Prior episode of hypoglycemia |
| Older age |
| Chronic kidney disease |
| Congestive heart failure |
| Liver Failure  |
| Sepsis |
| Malnutrition |
| Erratic eating patterns / Nutritional interruptions / Lack of access to carbohydrates |
| Malignancies |
| Insulin regimen |
| Type 1 diabetes |
| Mental status changes |
| Certain concomitants use of medications |
| Duration of diabetes |

The development of hypoglycemia is associated with adverse hospital outcomes (29; 30; 117; 118; 124; 144; 149-155). Turchin et al. examined data from 4,368 admission episodes for people with diabetes, of which one-third were on regular insulin therapy (30). Patients experiencing inpatient hypoglycemia experienced a 66% increased risk of death within one year and spent 2.8 days longer in the hospital compared to those not experiencing hypoglycemia. A 2019 systematic review and meta-analysis of hospital-acquired hypoglycemia in non-ICU patients suggested that adults exposed to glucose levels <72 mg/dl (<4.0 mmol/l) experienced a mean increased length of hospital stay of 4.1 days (95% CI 2.36 – 5.79) compared to those who did not experience hypoglycemia (144). The same dataset suggested an increased relative risk of in-hospital mortality for non-ICU patients of 2.09 (95% CI 1.64 – 2.67) (144). There was a non-significant reduction in mortality for those in ICU of 0.75 (95% CI 0.49 – 1.16) (144). The odds ratio (95% confidence interval) for mortality associated with one or more episodes was 2.28 (1.41-3.70, p=0.0008) among a cohort of 5,365 patients admitted to a mixed medical-surgical ICU (142). In a larger cohort of over 6,000 patients, hypoglycemia was associated with longer ICU stays and greater hospital mortality, especially for patients with more than one episode of hypoglycemia (29). These data strengthen the argument to have potentially less strict glycemic targets for those not on ICU (32; 137). For example, if an individual has a glucose of 75 mg/dl (4.2 mmol/l), and is on an intravenous insulin infusion, by the time their bedside capillary glucose is next measured, they may have a glucose well below 72 mg/dl (4.0 mmol/l), thus they have come to potential harm. Indeed, data published from previous NaDIA surveys and NaDIA Harms using data from over 100 hospitals across the UK showed several serious adverse events, including seizures, permanent cerebral damage, cardiac arrests, and deaths. Insulin therapy was implicated in several of these events (33; 34; 156; 157). The counterargument is that there are initiatives to reduce the risk of developing inpatient hypoglycemia and having national guidance has led to improved patient care overall (106; 158). As with the outpatient population, the increased use of technology may help avoid hypoglycemia (159).

Hypoglycemia has been associated with adverse cardiovascular outcomes, such as increased myocardial contractility, prolonged QT interval (possibly due to the rapid drop in potassium concentrations due to the increased circulating epinephrine and norepinephrine), ischemic electrocardiogram changes and repolarization abnormalities, angina, arrhythmias, increased inflammation, and sudden death, (51; 160-162). The mechanisms for the poor outcome have yet to be entirely understood. Still, hypoglycemia has been associated with increases in pro-inflammatory cytokines (TNFα, IL-1β, IL-6, and IL-8), markers of lipid peroxidation, acute changes in endothelial dysfunction with associated vasoconstriction, increased blood coagulability, cellular adhesion, and oxidative stress (163; 164).

Despite these observations, the direct causal effect of iatrogenic hypoglycemia on outcome is still debatable. Kosiborod et al. reported that spontaneous hypoglycemia, but not insulin–induced hypoglycemia, was associated with higher hospital mortality (152). Similarly, another study among 31,970 patients also reported that hypoglycemia is associated with increased in-hospital mortality. Still, the risk was limited to patients with spontaneous hypoglycemia and not to patients with drug-associated hypoglycemia (165). These studies raise the possibility that hypoglycemia, like hyperglycemia, despite the biochemical and other changes described, is a marker of disease burden rather than a direct cause of death.

# RECOMMENDATIONS FOR MANAGING HYPERGLYCEMIA IN THE HOSPITAL ENVIRONMENT

### Knowledge of Diabetes Management Amongst Medical Staff

### The burden on inpatient diabetes falls most frequently on junior medical staff, who often have little or no specialist diabetes training. As such, it is perhaps unsurprising that errors occur. In the UK, a survey of junior doctors showed that unlike other commonly encountered medical conditions, such as acute asthma or angina, their knowledge about and confidence in managing diabetes was significantly lower (166). In 2019, this was also shown in a multicenter study from the US – with the major difference being that whilst most staff felt confident and comfortable managing diabetes, when challenged on how to manage certain situations, and in particular identifying glucose targets for those who were critically ill or the threshold for defining hypoglycemia, their confidence was far higher than their knowledge – a potentially devastating combination (167). Given the high prevalence of diabetes amongst hospital inpatients, essential diabetes management should be part of mandatory training. However, studies have found that despite the implementation of training programs, structured staff education has not shown to be of significant benefit in terms of improved patient outcomes (168; 169)

### Management of Inpatient Hyperglycemia in the ICU

Insulin is the best way to control hyperglycemia in the inpatient setting, especially in critically ill patients. A variable-rate intravenous insulin infusion is the preferred method to achieve the recommended glycemic target (ADA Standards of Care 2025). The short half-life of intravenous insulin makes it ideal in this setting because it allows flexibility in the event of unpredicted changes in an individual’s health, medications, and nutrition.

When someone is identified as having hyperglycemia (blood glucose ≥180 mg/dl [≥10.0 mmol/l]), a variable rate intravenous insulin infusion should be started to maintain blood glucose levels <180 mg/dl (<10.0 mmol/l). A variety of intravenous infusion protocols are effective in achieving glycemic control with a low rate of hypoglycemic events and in improving hospital outcomes (73; 86; 113; 121; 170-174). A proper protocol should allow flexible blood glucose targets to be modified based on the individual’s clinical situation. Further, it should have clear instructions about the blood glucose threshold for initiating an insulin infusion and the initial rate. The appropriate fluids should also be prescribed. It should be validated to avoid hyperglycemia if adjusted too slowly and hypoglycemia if adjusted too fast. Accurate insulin administration requires a reliable infusion pump that can deliver the insulin dose in increments of 0.1 units per hour (138; 172).

There is no ideal insulin protocol for managing hyperglycemia in the critically ill patient. In addition, no clear evidence demonstrates the benefit of one protocol/algorithm versus any other (138). Implementing any of these algorithms requires close follow-up by the nursing staff and is prone to human errors. Some institutions have developed computerized protocols that can be implemented to avoid errors in dosing (138; 175-179). Essential elements that increase protocol success of continuous insulin infusion are: 1) rate adjustment considers the current and previous glucose value and the current rate of insulin infusion, 2) rate adjustment considers the rate of change (or lack of change) from the previous reading, and 3) frequent glucose monitoring (hourly until stable glycemia is established, and then at least every 2 – 3 hours) (138; 171; 180-182).

Several computer-based algorithms aiming to direct the nursing staff in adjusting the insulin infusion rate have become commercially available (175-177; 179; 183). Retrospective cohorts and controlled trials have reported a more rapid and tighter glycemic control with computer-guided algorithms than standard paper form protocols in ICU patients (176; 184), as well as lower glycemic variability than patients treated with the standard insulin infusion regimens. Despite differences in glycemic control between insulin algorithms, another study showed no difference between computerized protocols versus conventional glucose control (128). Thus, most insulin algorithms appear to be appropriate alternatives for managing hyperglycemia in critically ill patients, and the choice depends upon the physician’s preferences, staffing availability, and cost considerations. As mentioned, the increasing implementation of available technology, in particular the use of closed loops should improve the management of dysglycemia over the coming years (185-187).

# Managing Hyperglycemia in the Non-ICU Setting

Subcutaneous insulin is the preferred therapeutic agent for glucose control in those admitted to non-ICU settings under general medicine and surgery. A recent study suggested that the use of bolus correction doses of subcutaneous insulin (“subcutaneous sliding scale insulin” (SSI)) is an acceptable way of controlling dysglycemia, particularly in those whose admission glucose levels were <180 mg/dl (10 mmol/l) (188; 189). However, many studies do not agree and advocate against using this method as the only way to control glucose levels because it results in undesirable hypoglycemia and hyperglycemia or inadequately controls dysglycemia (109; 190-193). It has become evident in recent years that the use of scheduled subcutaneous insulin therapy with basal (e.g. glargine, detemir or degludec) once daily or with intermediate-acting insulin (NPH) given twice daily alone or in combination with short (regular) or rapid-acting insulin (lispro, aspart, glulisine) prior to meals is effective and safe for the management of most patients with hyperglycemia and diabetes (20; 108; 194).

The basal-bolus (prandial) insulin regimen is considered the physiologic approach as it addresses the three components of insulin requirement: basal (what is required in the fasting state), nutritional (what is needed for peripheral glucose disposal following a meal), and supplemental (what is necessary for unexpected glucose elevations, or to dispose of glucose in hyperglycemia (195).

A prospective, randomized multi-center trial compared the efficacy and safety of a basal/bolus insulin regimen with basal-bolus regimen and SSI in people with type 2 diabetes admitted to a general medicine service (139). The use of a basal-bolus insulin regimen improved blood glucose control more than the subcutaneous sliding scale alone. A blood glucose target <140 mg/dl (<7.8 mmol/l) was achieved in 66% of those in the glargine plus glulisine group and 38% in the sliding scale group (139). The incidence of hypoglycemia, defined as a BG <60 mg/dl (<3.3 mmol/l), was less than 5% in those treated with basal-bolus or SSI. A different study on general surgery inpatients also compared the efficacy and safety of a basal-bolus regimen to SSI in those with type 2 diabetes (71). The basal-bolus regimen resulted in a significant improvement in glucose control and a reduction in the frequency of the composite of postoperative complications, including wound infection, pneumonia, respiratory failure, acute renal failure, and bacteremia.

Multi-dose human NPH and regular insulin have been compared to basal-bolus treatment with insulin analogs in an open-label, controlled, multicenter trial in 130 medical admissions with type 2 diabetes (196). This study found that both treatment regimens significantly improved inpatient glycemic control with a glucose target of <140 mg/dl (<7.8 mmol/l) before meals and no difference in the rate of hypoglycemic events. Thus, a similar improvement in glycemic control can be achieved with either basal-bolus therapy with insulin analogs or with NPH/regular human insulin in people with type 2 diabetes.

Most people in the hospital have reduced caloric intake due to a lack of appetite, medical procedures, or surgical intervention. In the Basal Plus trial, people with type 2 diabetes who were treated with diet, oral antidiabetic agents, or low-dose insulin (≤ 0.4 unit/kg/day) prior to admission were randomized to receive a standard basal-bolus regimen with glargine once daily and glulisine before meals or a single daily dose of glargine. In addition, supplemental doses of glulisine were administered for correction of hyperglycemia (>140 mg/dl [>7.8 mmol/l]) per sliding scale (197). This study reported that the basal approach resulted in similar improvement in glycemic control and the frequency of hypoglycemia compared to a standard basal-bolus regimen (197). Thus, in insulin-naive individuals or those receiving low-dose insulin on admission, as well as those with reduced oral intake, the use of a basal plus regimen is an effective alternative to basal-bolus (108).

The recommended total daily insulin dose should start between 0.3 to 0.5 units per Kg (139; 147; 198; 199) for most people with diabetes. Starting doses greater than 0.6 – 0.8 units/kg/day have been associated with 3-fold higher odds of hypoglycemia than doses lower than 0.2 U/kg/day. In elderly individuals or those with impaired renal function, lower initial daily doses (≤ 0.3 units/kg) may lower the risk of hypoglycemia (200).

# Hospital Use of Non-Insulin Therapy in Non-Critical Care Settings

Several other classes of non-insulin glucose-lowering agents have been tried in the hospital setting. However, most are not suitable for use. Metformin, while the first line for type 2 diabetes in the outpatient setting, may not be appropriate where there is any evidence of dehydration, renal impairment, or if intravenous contrast is due to be administered due to the risk of lactic acidosis or worsening of renal function (195). Despite the lack of robust evidence of benefit, it remains in everyday use in many countries (201). Thiazolidinediones are excellent at lowering glucose but are used rarely, and possibly inappropriately, in hospitalized patients because they take several weeks to reach their maximum effect, may precipitate heart failure, and may cause peripheral edema due to fluid retention (202-204).

Sulfonylureas work rapidly and are often the drugs of choice for worsening diabetes in an outpatient setting (205). They remain in everyday use in many countries, with up to 20% of inpatients with diabetes in the USA and UK remaining on them (140; 203). However, they increase the risk of hypoglycemia. There is data to show that they remain one of the most frequent causes of inpatient hypoglycemia, thus extending the length of hospital stay and increasing the risk of inpatient mortality (141; 206-208).

Oral glucose-lowering medication use is limited by the delay and unpredictability of onset of action, and there is also concern regarding the cardiovascular effects of sulfonylureas and the contraindication of metformin use in patients with renal or liver dysfunction (19; 209). Recent work using the sodium-glucose co-transporter 2 inhibitors for corticosteroid-induced hyperglycemia in acute exacerbation of chronic obstructive pulmonary disease (COPD) or used in COVID infections failed to demonstrate an improvement in outcomes (210; 211). Indeed, despite their clear benefits in the outpatient population with and without diabetes, robust evidence for the benefit of SGLT2i use in the inpatient population (in people with diabetes) is lacking (212; 213).

The use of oral antidiabetic agents was not recommended in previous guidelines because of the need for more safety and efficacy studies in the inpatient setting (20). However, increasing evidence indicates that treatment with dipeptidyl peptidase-4 (DPP4) inhibitors, alone or in combination with basal insulin, is safe and effective in general medicine and surgery with mild to moderate hyperglycemia (48). In a pilot study, general medicine and surgical inpatients with blood glucose between 140 and 400 mg/dl (7.8 – 22.2 mmol/l) treated with diet, oral antidiabetic drugs, or low-dose insulin (≤0.4 U/kg/day) were randomized to sitagliptin once daily, sitagliptin and basal insulin, or basal-bolus insulin (214). All groups received correction doses of lispro before meals and bedtime for blood glucose >140 mg/dl (>7.8 mmol/l). In those with mild-moderate hyperglycemia (<180 mg/dl [<10 mmol/l]), the use of sitagliptin plus supplemental (correction doses) or in combination with basal insulin resulted in no significant differences in mean daily blood glucose, frequency of hypoglycemia or the number of treatment failures compared to the basal-bolus regimen (214). The SITA-HOSPITAL trial, a multicenter, randomized controlled study in 279 general medicine and surgery individuals with type 2 diabetes previously treated with oral anti-diabetic agents or low-dose insulin (<0.6 U/kg/d), also reported similar glycemic control, hypoglycemia rate, hospital length-of-stay, treatment failures or hospital complications (including acute kidney injury or pancreatitis) between the combination of oral sitagliptin plus basal insulin to the more labor-intensive basal-bolus insulin regimen (215).

Analysis from prospective studies using DPP4-i in various inpatient situations with type 2 diabetes (T2D) reported that treatment with DPP4-i alone or with basal insulin suggested they were safe and lowered glucose concentrations without increasing the risk of hypoglycemia (216; 217).

For people with type 2 diabetes hospitalized with heart failure, the ADA has recommended that the use of a sodium-glucose cotransporter 2 (SGLT2) inhibitor be initiated or continued during hospitalization and upon discharge if there are no contraindications and after recovery from the acute illness (218-221). In patients with acute heart failure, empagliflozin was well tolerated, resulting in significant clinical benefits, including heart failure readmissions and quality of life (221).However, SGLT2 inhibitors should be avoided in cases of severe illness, in people with type 1 diabetes, ketonemia, or ketonuria, and during prolonged fasting and surgical procedures. Proactive adjustment of diuretic dosing is recommended during hospitalization and/or discharge, especially in collaboration with a cardiology/heart failure consult team. The FDA has warned that SGLT2 inhibitors should be stopped three days before scheduled surgeries (4 days in the case of ertugliflozin) (222). This differs from the UK guideline, which states that these drugs should be omitted from the day before a procedure (223).

**Staffing Levels in the Hospital**

Inadequate levels of appropriately knowledgeable staff are a concern for patients with diabetes (224). An insufficient level of specialist diabetes staff is a factor that inhibits safe and optimal care (34). Recently, the UK JBDS group developed a simple calculator into which individual teams could enter data to calculate their staffing needs (49). That data showed the discrepancy between the number of people delivering care and the number of people that specialist teams felt was necessary to provide safe and effective care for five days or seven days per week. This was for senior medical staff, specialist nursing staff, dieticians, podiatrists, pharmacists and psychologists (49).

### Glucose Monitoring in the Hospital

All patients admitted to the hospital with a diagnosis of diabetes and those with newly discovered hyperglycemia should be monitored closely (21). The frequency and method of monitoring and the schedule of the blood glucose checks will depend on the nutritional intake, patient treatment, and insulin schedule, as well as the ability of the individual to self-manage their diabetes (225). There is some controversy regarding the best method to monitor blood glucose. However, considering the convenience and wide availability of capillary point of care (POC) testing, we suggest this as the best approach if done with a monitoring device that has demonstrated accuracy (226-228). When using POC blood glucose meters, it is important to keep several things in mind. In particular, overall clinical conditions that might affect the POC value, such as hemoglobin level, perfusion, and medications, as well as the policy of the health care organization in guiding the patient and the staff on the use of POC devices or newer technologies.

Bedside point-of-care (POC) capillary glucose testing is usually ordered before meals and bedtime to assess glycemic control and adjust insulin therapy in the hospital (19; 228). However, this approach has been shown to fail to detect hypoglycemia, particularly nocturnal and asymptomatic hypoglycemia, which is a common scenario in the hospital setting (229; 230).

Continuous glucose monitoring (CGM) has increased over the last few years, helping to improve glycemic management in the ICU. The use of this technology was accelerated during the COVID pandemic, where the use of CGM meant that close contact with sick individuals was avoided using remote sensing (231-234). The use of CGM is questioned, with the accuracy of readings when dealing with hypoglycemia or in the operating room (235; 236). However, in general, most studies have been associated with overall benefit (234; 237; 238).

CGM is reliable compared to point-of-care testing and laboratory values in the inpatient setting. It is currently being evaluated for managing ICU and general ward patients (159; 185; 235; 239-242). Studies have shown that CGM offers advantages over intermittent capillary monitoring in the ICU. CGM can help identify and prevent severe hyperglycemia and hypoglycemia by allowing for more rapid and accurate adjustments to insulin infusions compared to capillary blood glucose testing. Research has also demonstrated that CGM is better at detecting hypoglycemia, predominantly asymptomatic and nocturnal hypoglycemia, than capillary glucose testing (243; 244). Additionally, CGM is as safe and effective as standard care in hospitalized patients and can lead to a significant decrease in recurrent hypoglycemia events compared with standard point-of-care testing (243; 245). Regulatory approval for CGM use in hospitals is still pending, but consensus guidelines suggest that the use of CGM in the hospital setting has the potential to provide a better glycemic assessment than capillary glucose testing (Walia et al.; other, Endo Soc Guidelines). Furthermore, advanced technology in guiding insulin therapy using machine learning and artificial intelligence is being integrated more frequently into diabetes care (246). A proof-of-concept trial in patients with type 2 diabetes evaluated the efficacy and safety of a model-based reinforcement learning framework in titrating insulin dosing. After applying the intervention, the mean daily BG was lower by approximately 56 mg/dl (3 mmol/l) with no severe hypo- or hyperglycemia (247).

The American Diabetes Association (ADA) and UK JBDS recently recommended that people with diabetes who use a personal continuous glucose monitoring (CGM) device should be allowed to continue during hospitalization (48; 159; 248). Both organizations also recommend that confirmatory point-of-care (POC) glucose measurements be used for insulin dosing decisions, hypoglycemia assessment, and treatment.

A recent survey of inpatient teams across the UK showed significant variations in accessing and using technologies (249). These included networked glucose and ketone meters, and wearable diabetes technologies such as CGM, pumps, or closed loop systems. While almost two-thirds of respondents agreed that technology would help prevent hypoglycemia, there was a wide variety of specialist diabetes nursing or medical staff support available to help non-specialists, particularly on weekends or outside of regular working hours (249).

**Medical Nutrition Therapy (MNT) in Hospitalized Patients with Diabetes**

Medical nutrition therapy (MNT) is a key component of the comprehensive management of diabetes and hyperglycemia in the inpatient setting. Maintaining adequate nutrition is essential for glycemic control and to meet adequate caloric demands. Caloric demand in acute illness will differ from that in the outpatient setting. Achieving the proper nutritional balance in the inpatient setting is challenging. Anyone admitted to the hospital with diabetes or hyperglycemia should be assessed to determine the need for a modified diet to meet caloric demands.

The general approach to addressing MNT in the inpatient setting is usually based on expert opinions and patients' needs. Limited data exist regarding the best approach or method to achieve the ideal caloric supply. To determine the best approach, method, and caloric needs of their patients, providers should work closely with the nutrition professional.

All patients with diabetes or hyperglycemia should receive an individualized assessment. Most patients will generally receive adequate caloric needs with 3 discrete meals daily. Further, the metabolic need for patients with diabetes is usually provided by 25 to 35 calories/kg, whereas some critically ill patients might require less than 15 to 25 calories/kg per day (250; 251). A consistent carbohydrate meal-planning system might help to facilitate glycemic control and insulin dosing in the inpatient setting. Most patients require 1,500-2000 calories daily with 12-15 grams of carbohydrates per meal (19). Ideally, the carbohydrates should come from low glycemic index foods such as whole grains and vegetables.

Those individuals unable to achieve these goals should be evaluated to determine the need for enteral or parenteral nutrition. Enteral nutrition is the second-best option after oral nutrition and should be preferred over parenteral nutrition in hospitalized individuals (252-254). There are several advantages of enteral feeding versus parenteral feeding, including low cost, low risk of complications, a physiologic route, less risk for gastric mucosa atrophy, and lower risk of infectious and thrombotic complications compared with the latter form of therapy (252-254). The benefit of parental nutrition has been documented in critically ill patients. However, some research has shown a detrimental effect on patients with diabetes and hyperglycemia. Parental nutrition should be considered only in patients who cannot receive enteral nutrition and should be coordinated with the institution’s parenteral nutrition team. There has been guidance published in the surgical population on peri-operative nutrition, but the recommendations for people with diabetes is lacking because the literature remains scanty (251). A recent UK survey of diabetes teams showed no consensus on enteral feeding regimens (253). For those tube-fed, there were 3 main regimens: continuous 24-hour feeding, a single feed with one break in 24 hours, or multiple feeds in 24 hours. In addition, there were multiple insulin regimens used: premixed insulin, isophane insulin, analog basal insulin, variable rate intravenous insulin, or basal-bolus insulin. None of these provided adequate glycemic control (253).

Enteral and parenteral nutrition can prevent the effects of starvation and malnutrition (252). Enteral nutrition over parenteral nutrition is preferred whenever possible due to a lower risk of infectious and thrombotic complications (254-256). Standard enteral formulas reflect the reference values for macro- and micronutrients for a healthy population and contain 1-2 cal/ml. Most standard formulas contain whole protein, lipids in the form of long-chain triglycerides, and carbohydrates. Standard diabetes-specific formulas provide low amounts of lipids (30% of total calories) combined with a high carbohydrate (257) content (55–60% of total calories); however, newer “diabetic” formulas have replaced part of carbohydrates with monounsaturated fatty acids (up to 35% of total calories) and also include 10-15 g/l dietary fiber and up to 30% fructose (257; 258).

“Diabetic” enteral formulas containing low-carbohydrate high–monounsaturated fatty acid (LCHM) are preferable to standard high-carbohydrate formulas in hospitalized patients with type 1 and type 2 diabetes (257; 258). In a meta-analysis of studies comparing relatively newer enteral LCHM formulas with older formulations, the postprandial rise in blood glucose was reduced by 18- 29 mg/dl [1.0-1.6 mmol/l] with the newer formulations (258). Table 4 depicts the composition of standard and diabetic-specific enteral formulas commonly used in hospitalized patients.

|  |
| --- |
| **Table 4. Composition of Standard and Diabetic Specific Enteral Formulas Commonly Used in Hospitalized Patients in the USA** |
|  | **Calories (kcal/mL)** | **Carbohydrate (g/l)** | **Fat (g/l)** | **Protein (g/l)** | **Manufacture** |
| **Standard formula** |  |
| Jevity® 1.0 Cal | 1.0 | 140 | 35 | 40 | Abbott Nutrition |
| Nutren® 1.0 | 1.0 | 109 | 27 | 70 | Nestle Nutrition |
| Osmolite® 1.2 Cal | 1.2 | 158 | 39 | 56 | Abbott Nutrition |
| Jevity® 1.2 | 1.2 | 169 | 39 | 56 | Nestle Nutrition |
| Fibersource® HN | 1.2 | 164 | 40 | 54 | Nestle Nutrition |
| Isosource® 1.5 Cal | 1.5 | 176 | 60 | 68 | Nestle Nutrition |
| Jevity® 1.5 | 1.5 | 216 | 50 | 64 | Nestle Nutrition |
| **Diabetes specific formula** |
| Glucerna® 1.0 Cal | 1.0 | 75 | 54 | 50 | Abbott Nutrition |
| Nutren® Glytrol® | 1.0 | 100 | 48 | 45 | Nestle Nutrition |
| Glucerna® 1.2 Cal | 1.2 | 114 | 60 | 60 | Abbott Nutrition |
| Diabetisource® AC | 1.2 | 100 | 59 | 60 | Nestle Nutrition |
| Glucerna® 1.5 Cal | 1.5 | 133 | 75 | 83 | Abbott Nutrition |

The UK Joint British Diabetes Societies has updated its guidelines for the management of diabetes in enterally fed people (259).

### Corticosteroid Therapy – Impact on Blood Glucose

Steroid use in hospitalized patients is common. A single-center cross-sectional study showed that 12.8% of all the people in the hospital were on glucocorticoids (260). Steroids may be administered by various regimes and at variable doses. A single daily dose of steroid (e.g., prednisolone/prednisone) in the morning may be the most standard mode of administration (205; 260-262). Limbachia et al. showed that, in susceptible individuals, steroid use will often result in a rise in blood glucose by late morning that continues through to the evening (263). Overnight, the blood glucose generally falls back to baseline levels by the following day. They also showed the differential effects between different steroid types, with oral or IV dexamethasone or methylprednisolone leading to higher glucose excursions than prednisolone or hydrocortisone (262). Thus, treatment should be tailored to treating the hyperglycemia while avoiding nocturnal and early morning hypoglycemia. Multiple daily doses of steroid, be it intravenous hydrocortisone or oral dexamethasone, can cause a hyperglycemic effect throughout the 24-hour period. It may be, however, that a twice-daily premixed or basal-bolus regimen may need to be started if oral medication or once-daily insulin proves insufficient to control hyperglycemia (205). Close attention will therefore need to be paid to blood glucose monitoring, and early intervention may be necessary.

Glucose levels in most individuals can be predicted to rise approximately 4 to 8 hours following the administration of once-daily oral steroids and sooner following the administration of intravenous steroids. Again, capillary blood glucose monitoring is paramount to guide appropriate therapeutic interventions. Conversely, glucose levels may improve to pre-steroid levels 24 hours after intravenous steroids are discontinued. When oral steroids are weaned down, the glucose levels may decline in a dose-dependent fashion, but this may not occur, particularly in those with pre-existing undiagnosed diabetes.

At the commencement of steroid therapy, or for those already on a supraphysiological dose of corticosteroid, capillary blood glucose testing should occur before meals and at bedtime, in particular before lunch or evening meal, when the hyperglycemic effects of a morning dose of steroid are likely to be greatest (205; 262).

Subcutaneous insulin using a basal or multiple daily injection regimen will likely be the most appropriate choice for most patients to achieve glycemic control in the event of hyperglycemia. While the UK has advocated for short-acting sulfonylureas (205), the morning administration of basal human insulin may closely fit the glucose excursion induced by a single morning dose of oral steroid. Basal analog insulin may be appropriate if hyperglycemia is present for more prolonged periods. However, if long-acting insulin analogs are used in this context, care should be taken to identify and protect against hypoglycemia overnight and in the early morning. Subsequent titration of the insulin dose may be required to maintain glucose control in the face of increasing or decreasing the steroid dose.

When a patient is discharged from the hospital on steroid therapy, a clear strategy for managing hyperglycemia or potential hyperglycemia and the titration of treatment to address the hyperglycemia should be communicated to the community diabetes team and primary care team. Patients who commenced on steroids as inpatients and were discharged after a short stay with the intention of continuing high-dose steroids should receive standard diabetes education, encompassing the risks associated with hyperglycemia and hypoglycemia.

**Closed Loop Technology**

Several organizations have recommended that people who are well enough to do so should continue to use their insulin pumps in hospitals (108; 109; 240; 264). However, only a few recent studies have reported using closed-loop systems, also referred to as the artificial pancreas or automated insulin delivery systems, in hospitalized inpatients. Small randomized trials have reported good efficacy with improved time in target and lower mean daily blood glucose without an increased rate of hypoglycemia in the ICU (265-267) and non-ICU settings (268-271). However, some of these studies were done in those with type 2 diabetes (268; 270). In one non-ICU study, the time in the target range between 100-180 mg/dl (5.6-10.0 mmol/l) was reported as 59.8% in patients using the closed-loop technology compared to 38.1% with standard subcutaneous insulin regimen (269).

Similarly, a closed-loop study in patients receiving nutritional support also reported higher time in target glucose (68% vs 36.4%) and lower mean glucose values (153 vs 205 mg/dl [8.5-11.4 mmol/l]) compared to a standard insulin regimen (270). As with the use of CGM in the hospital, treatment with artificial pancreas is still experimental, and larger studies are needed to prove its safety and efficacy in ICU and non-ICU settings. Further challenges lie ahead because of the unfamiliarity of these systems, with non-specialist staff the primary carers for people with diabetes.

The ADA has recommended that insulin pumps or automated insulin delivery (closed-loop) systems be continued for hospitalized individuals with diabetes when clinically appropriate. Confirmatory POC blood glucose measurements should be used for insulin-dosing decisions and for assessing and treating hypoglycemia. However, this depends on the availability of required supplies and resources, proper training, ongoing competency assessments, and the implementation of institutional diabetes technology protocols (48).

As with the CGM, those who are well and can self-manage can look after their devices and diabetes. However, in those who are unwell or incapacitated, the systems must be disengaged from automatic and set to ‘manual’ mode to allow the diabetes teams to help manage the diabetes. The systems may not also be able to cope with the acute changes that occur in the hospital, including (but not limited to) change in oral carbohydrate intake, the use of glucocorticoids or other medications inducing insulin resistance; peri-operative use, nausea and vomiting; enteral or parenteral nutrition. Once again, the use of ‘manual’ mode is recommended in these situations, and the diabetes is managed in conjunction with the specialist diabetes team.

**REFERENCES**

1. IDF Diabetes Atlas 2021 [article online], 2021. Available from <https://diabetesatlas.org/>.

2. National Diabetes Statistics Report - 2024 [article online], 2024. Available from <https://www.cdc.gov/diabetes/php/data-research/index.html>.

3. Koyama AK, Cheng YJ, Brinks R, Xie, Gregg EW, Hoyer A, Pavkov ME, Imperatore G. Trends in lifetime risk and years of potential life lost from diabetes in the United States, 1997–2018. PLOS ONE 2022;17:e0268805

4. Pournaras DJ, Photi ES, Barnett N, Challand CP, Chatzizacharias NA, Dlamini NP, Doulias T, Foley A, Hernon J, Kumar B, Martin J, Nunney I, Panagiotopoulou I, Sengupta N, Shivakumar O, Sinclair P, Stather P, Than MM, Wells AC, Xanthis A, Dhatariya K. Assessing the quality of primary care referrals to surgery of patients with diabetes in the East of England: A multi-centre cross-sectional cohort study. International Journal of Clinical Practice 2017;71:e12971

5. Jiang HJ, Stryer D, Friedman B, Andrews R. Multiple hospitalizations for patients with diabetes. Diabetes Care 2003;26:1421-1426

6. Donnan PT, Leese GP, Morris AD. Hospitalizations for people with type 1 and type 2 diabetes compared with the nondiabetic population of Tayside, Scotland: a retrospective cohort study of resource use. Diabetes Care 2000;23:1774-1779

7. Harding JL, Benoit SR, Gregg EW, Pavkov ME, Perreault L. Trends in rates of infections requiring hospitalization among adults with versus without diabetes in the U.S., 2000 - 2015. Diabetes Care 2020;43:106-116

8. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: An independent marker of in-hospital mortality in patients with undiagnosed diabetes. Journal of Clinical Endocrinology Metabolism 2002;87:978-982

9. National Diabetes Statistics Report 2022 [article online], 2022. Available from <https://www.cdc.gov/diabetes/data/statistics-report/index.html>.

10. Zhang Y, McKeever Bullard K, Imperatore G, Holliday CS, Benoit SR. Proportions and trends of adult hospitalizations with diabetes, United States, 2000–2018. Diabetes Research and Clinical Practice 2022;187:109862

11. National Diabetes Inpatient Audit (NaDIA) - 2019 [article online], 2020. Available from <https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-inpatient-audit/2019>.

12. Sampson MJ, Dozio N, Ferguson B, Dhatariya K. Total and excess bed occupancy by age, speciality and insulin use for nearly one million diabetes patients discharged from all English Acute Hospitals. Diabetes Research & Clinical Practice 2007;77:92-98

13. American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care 2018;41:917-928

14. Parker ED, Lin J, Mahoney T, Ume N, Yang G, Gabbay RA, ElSayed NA, Bannuru RR. Economic costs of diabetes in the U.S. in 2022. Diabetes Care 2023;47:26-43

15. Friel KM, Gillespie P, Coates V, McCauley C, McCann M, O’Kane M, McGuigan K, Khamis A, Manktelow M. Estimating and examining the costs of inpatient diabetes care in an Irish Public Hospital. Diabetic Medicine 2022;39:e14753

16. Bommer C, Heesemann E, Sagalova V, Manne-Goehler J, Atun R, Barnighausen T, Vollmer S. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. Lancet Diabetes and Endocrinology 2017;5:423-430

17. Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, Barnighausen T, Davies J, Vollmer S. Global economic burden of diabetes in adults: Projections from 2015 to 2030. Diabetes Care 2018;41:963-970

18. Nolan JJ, O'Halloran D, McKenna TJ, Firth R, Redmond S. The cost of treating type 2 diabetes (CODEIRE). Irish Medical Journal 2006;99:307-310

19. Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, Seley JJ, Van den Berghe G. Management of hyperglycemia in hospitalized patients in non-critical care setting: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology Metabolism 2012;97:16-38

20. Moghissi ES, Korytkowski MT, Dinardo MM, Hellman R, Hirsch IB, Inzucchi S, Ismail-Beigi F, Kirkman MS, Umpierrez GE. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009;32:1119-1131

21. Dhatariya K, James J, Kong M-F, Berrington R. Diabetes at the front door. A guideline for dealing with glucose related emergencies at the time of acute hospital admission from the Joint British Diabetes Society (JBDS) for Inpatient Care Group. Diabetic Medicine 2020;37:1578-1589

22. Dhatariya K, Mustafa OG, Rayman G. Safe care for people with diabetes in hospital. Clinical Medicine 2020;20:21-27

23. A good inpatient diabetes service [article online], 2019. Available from <https://abcd.care/resource/jbds-14-good-inpatient-diabetes-service>.

24. NICE SUGAR investigators. Intensive versus conventional glucose control in critically ill patients. New England Journal of Medicine 2009;360:1283-1297

25. Hulkower RD, Pollack RM, Zonszein J. Understanding hypoglycemia in hospitalized patients. Diabetes Management (Lond) 2014;4:165-176

26. McDonnell ME, Umpierrez GE. Insulin therapy for the management of hyperglycemia in hospitalized patients. Endocrinology & Metabolism Clinics of North America 2012;41:175-201

27. Qaseem A, Humphrey LL, Chou R, Snow V, Shekelle P, Physicians for the Clinical Guidelines Committee of the American College of Physicians. Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine 2011;154:260-267

28. Cook CB, Kongable GL, Potter DJ, Abad VJ, Leija DE, Anderson M. Inpatient glucose control: a glycemic survey of 126 U.S. hospitals. Journal of Hospital Medicine 2009;4:E7-E14

29. NICE SUGAR investigators. Hypoglycemia and risk of death in critically ill patients. New England Journal of Medicine 2012;367:1108-1118

30. Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, Pendergrass ML. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care 2009;32:1153-1157

31. Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T. Glycemic control, mortality, and hypoglycemia in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials. Intensive Care Medicine 2017;43:1-15

32. Levy N, Hall GM. National guidance contributes to the high incidence of inpatient hypoglycaemia. Diabetic Medicine 2019;36:120-121

33. National Diabetes Inpatient Audit - Harms 2020 England [article online], 2020. Available from <https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-inpatient-audit---harms/national-diabetes-inpatient-audit---harms-2020>.

34. National Diabetes Inpatient Safety Audit (NDISA) 2018-2021 [article online], 2022. Available from <https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-inpatient-safety-audit-ndisa/ndisa-2018-2021>.

35. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda AP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovic L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocrine Practice 2015;21:1-87

36. Jacobi J, Bircher N, Krinsley J, Agus M, Braithwaite SS, Duutschman C, Freire AX, Geehan D, Kohl B, Nasraway SA, Rigby M, Sands K, Schallom L, Taylor B, Umpierrez G, Mazuski J, Schunemann H. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Critical Care Medicine 2012;40:3251-3276

37. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009;32:1335-1343

38. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. Diabetes care in the hospital: Standards of care in diabetes—2023. Diabetes Care 2023;46:S267-S278

39. Swanson C, Potter D, Kongable G, Cook C. Update on inpatient glycemic control in hospitals in the United States. Endocrine Practice 2017;17:853-861

40. Schmeltz LR, DeSantis AJ, Thiyagarajan V, Schmidt K, Shea-Mahler E, Johnson D, Henske J, McCarthy PM, Gleason TG, McGee EC, Molitch ME. Reduction of surgical mortality and morbidity in diabetic patients undergoing cardiac surgery with a combined intravenous and subcutaneous insulin glucose management strategy. Diabetes Care 2007;30:823-828

41. Carpenter DL, Gregg SR, Xu K, Buchman TG, Coopersmith CM. Prevalence and impact of unknown diabetes in the ICU. Critical Care Medicine 2015;43:e541-e550

42. Desgrouas M, Demiselle J, Stiel L, Brunot V, Marnai R, Sarfati S, Fiancette M, Lambiotte F, Thille AW, Leloup M, Clerc S, Beuret P, Bourion A-A, Daum J, Malhomme R, Ravan R, Sauneuf B, Rigaud J-P, Dequin P-F, Boulain T. Insulin therapy and blood glucose management in critically ill patients: a 1-day cross-sectional observational study in 69 French intensive care units. Annals of Intensive Care 2023;13:53

43. Van Ackerbroeck S, Schepens T, Janssens K, Jorens PG, Verbrugge W, Collet S, Van Hoof V, Van Gaal L, De Block C. Incidence and predisposing factors for the development of disturbed glucose metabolism and DIabetes mellitus AFter Intensive Care admission: the DIAFIC study. Critical Care 2015;19:355

44. Kar P, Plummer MP, Ali Abdelhamid Y, Giersch EJ, Summers MJ, Weinel LM, Finnis ME, Phillips LK, Jones KL, Horowitz M, Deane AM. Incident diabetes in survivors of critical illness and mechanisms underlying persistent glucose intolerance: A prospective cohort study. Critical Care Medicine 2019;47:e103-e111

45. Gomez AM, Imitola Madero A, Henao Carrillo DC, Rondon M, Munoz OM, Robledo MA, Rebolledo M, Garcia Jaramillo M, Leon Vargas F, Umpierrez G. Hypoglycemia incidence and factors associated in a cohort of patients with type 2 diabetes hospitalized in general ward treated with basal bolus insulin regimen assessed by continuous glucose monitoring. Journal of Diabetes Science and Technology 2020;14:233-239

46. Greci LS, Kailasam M, Malkani S, Katz DL, Hulinsky I, Ahmadi R, Nawaz H. Utility of HbA1c levels for diabetes case finding in hospitalized patients with hyperglycemia. Diabetes Care 2003;26:1064-1068

47. Mazurek JA, Hailpern SM, Goring T, Nordin C. Prevalence of hemoglobin A1c greater than 6.5% and 7.0% among hospitalized patients without known diagnosis of diabetes at an urban inner city hospital. Journal of Clinical Endocrinology & Metabolism 2010;95:1344-1348

48. American Diabetes Association. 16. Diabetes care in the hospital: Standards of Care in Diabetes–2025. Diabetes Care 2025;48 (Suppl 1).

49. Dashora U, Flanagan D, Rayman G, Mustafa OG, Walden E, Dhatariya K, The Joint British Diabetes Societies for Inpatient Care. Optimal staffing for a good quality inpatient diabetes service. Diabetic Medicine 2023;40:e15151

50. Cryer PE. Hypoglycemia, functional brain failure, and brain death. Journal of Clinical Investigation 2014;117:868-870

51. Amiel SA, Aschner P, Childs B, Cryer PE, de Galan BE, Frier BM, Gonder-Frederick L, Heller SR, Jones T, Khunti K, Leiter LA, Luo Y, McCrimmon RJ, Pedersen-bjergaard U, Seaquist ER, Zoungas S. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes & Endocrinology 2019;7:385-396

52. Corssmit EP, Romijn JA, Sauerwein HP. Regulation of glucose production with special attention to nonclassical regulatory mechanisms: A review. Metabolism 2014;50:742-755

53. Boden G. Gluconeogenesis and glycogenolysis in health and diabetes. Journal of Investigative Medicine 2004;52:375-378

54. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis. Diabetes Care 2001;24:382-391

55. van de Werve G, Jeanrenaud B. Liver glycogen metabolism: An overview. Diabetes/Metabolism Reviews 1987;3:47-78

56. Gerich JE, Lorenzi M, Bier DM, Tsalikian E, Schneider V, Karam JH, Forsham PH. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin. Journal of Clinical Investigation 1976;57:875-884

57. Rizza RA, Mandarino LJ, Gerich JE. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. American Journal of Physiology - Endocrinology & Metabolism 1981;240:E630-E639

58. Dhatariya KK, Glaser NS, Codner E, Umpierrez GE. Diabetic ketoacidosis. Nature Reviews Disease Primers 2020;6:40

59. Dungan KM, Braithwaite SS, Preiser J-C. Stress hyperglycaemia. Lancet 2009;373:1798-1807

60. McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Critical Care Clinics 2001;17:107-124

61. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004;53:2079-2086

62. Chaudhuri A, Umpierrez GE. Oxidative stress and inflammation in hyperglycemic crises and resolution with insulin: implications for the acute and chronic complications of hyperglycemia. Journal of Diabetes and its Complications 2012;26:257-258

63. Reyes-Umpierrez D, Davis G, Cardona S, Pasquel FJ, Peng L, Jacobs S, Vellanki P, Fayfman M, Haw S, Halkos M, Guyton RA, Thourani VH, Umpierrez GE. Inflammation and oxidative stress in cardiac surgery patients treated to intensive versus conservative glucose targets. Journal of Clinical Endocrinology & Metabolism 2016;102:309-315

64. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress. Circulation 2002;106:2067-2072

65. Fan J, Li YH, Wojnar MM, Lang CH. Endotoxin-induced alterations in insulin-stimulated phosphorylation of insulin receptor, IRS-1, and MAP kinase in skeletal muscle. Shock 1996;6:164-170

66. Evans NR, Dhatariya KK. Assessing the relationship between admission glucose levels, subsequent length of hospital stay, readmission and mortality. Clinical Medicine 2012;12:137-139

67. Haddadin F, Clark A, Evans N, Dhatariya K. Admission blood glucose helps predict 1 year, but not 2 years, mortality in an unselected cohort of acute general medical admissions. International Journal of Clinical Practice 2014;69:643-648

68. Frisch A, Chandra P, Smiley D, Peng L, Rizzo M, Gatcliffe C, Hudson M, Mendoza J, Johnson R, Lin E, Umpierrez GE. Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. Diabetes Care 2010;33:1783-1788

69. Kotagal M, Symons RG, Hirsch IB, Umpierrez GE, Dellinger EP, Farrokhi ET, Flum DR. Perioperative hyperglycemia and risk of adverse events among patients with and without diabetes. Annals of Surgery 2016;261:97-103

70. Umpierrez G, Cardona S, Pasquel F, Jacobs S, Peng L, Unigwe M, Newton CA, Smiley-Byrd D, Vellanki P, Halkos M, Puskas JD, Guyton RA, Thourani VH. Randomized controlled trial of intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery: GLUCO-CABG trial. Diabetes Care 2015;38:1665-1672

71. Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, Umpierrez D, Newton C, Olson D, Rizzo M. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 Surgery). Diabetes Care 2011;34:256-261

72. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clinic Proceedings 2003;78:1471-1478

73. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Annals of Thoracic Surgery 1999;67:352-362

74. Montori VM, Bistrian BR, McMahon MM. Hyperglycemia in acutely ill patients. JAMA 2002;288:2167-2169

75. Adie SK, Ketcham SW, Marshall VD, Farina N, Sukul D. The association of glucose control on in-hospital mortality in the cardiac intensive care unit. Journal of Diabetes and its Complications 2023;37:108453

76. Levy N, Dhatariya K. Pre-operative optimisation of the surgical patient with diagnosed and undiagnosed diabetes: a practical review. Anaesthesia 2019;74:58-66

77. Falciglia M, Freyberg RW, Almenoff PL, D'Alessio DA, Render ML. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Critical Care Medicine 2009;37:3001-3009

78. Bruno A, Gregori D, Caropreso A, Lazzarato F, Petrinco M, Pagano E. Normal glucose values are associated with a lower risk of mortality in hospitalized patients. Diabetes Care 2008;31:2209-2210

79. Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care 2018;41:2127-2135

80. Blaha J, Mraz M, Kopecky P, Stritesky M, Lips M, Matias M, Kunstyr J, Porizka M, Kotulak T, Kolnikova I, Simanovska B, Zakharchenko M, Rulisek J, Sachl R, Anyz J, Novak D, Linder J, Hovorka R, Svacina S, Haluzik M. Perioperative tight glucose control reduces postoperative adverse events in nondiabetic cardiac surgery patients. Journal of Clinical Endocrinology & Metabolism 2015;100:3081-3089

81. Barmanray RD, Cheuk N, Fourlanos S, Greenberg PB, Colman PG, Worth LJ. In-hospital hyperglycemia but not diabetes mellitus alone is associated with increased in-hospital mortality in community-acquired pneumonia (CAP): a systematic review and meta-analysis of observational studies prior to COVID-19. BMJ Open Diabetes Research & Care 2022;10:e002880

82. Shiffermiller J, Anderson M, Thompson R. Postoperative length of stay in patients with stress hyperglycemia compared to patients with diabetic hyperglycemia: A retrospective cohort study. Journal of Diabetes Science and Technology 2024;18:556-561

83. Jones CE, Graham LA, Morris MS, Richman JS, Hollis RH, Wahl TS, Copeland LA, Burns EA, Itani KM, Hawn MT. Association between preoperative hemoglobin A1c levels, postoperative hyperglycemia, and readmissions following gastrointestinal surgery. JAMA Surgery 2017;152:1031-1038

84. Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. Free Radical Biology and Medicine 2011;50:567-575

85. Meza CA, La Favor JD, Kim DH, Hickner RC. Endothelial dysfunction: Is there a hyperglycemia-induced imbalance of NOX and NOS? International Journal of Molecular Science 2019;20

86. Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO, Floten HS, Starr A. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. Journal of Thoracic & Cardiovascular Surgery 2003;125:1007-1021

87. Krinsley JS, Maurer P, Holewinski S, Hayes R, McComsey D, Umpierrez GE, Nasraway SA. Glucose control, diabetes status, and mortality in critically ill patients. Mayo Clinic Proceedings 2017;92:1019-1029

88. van Vught LA, Holman R, de Jong E, de Keizer NF, van der Poll T. Diabetes is not associated with increased 90-day mortality risk in critically ill patients with sepsis. Critical Care Medicine 2017;45:e1026-e1035

89. Gunst J, Debaveye Y, Güiza F, Dubois J, De Bruyn A, Dauwe D, De Troy E, Casaer MP, De Vlieger G, Haghedooren R, Jacobs B, Meyfroidt G, Ingels C, Muller J, Vlasselaers D, Desmet L, Mebis L, Wouters PJ, Stessel B, Geebelen L, Vandenbrande J, Brands M, Gruyters I, Geerts E, De Pauw I, Vermassen J, Peperstraete H, Hoste E, De Waele JJ, Herck I, Depuydt P, Wilmer A, Hermans G, Benoit DD, Van den Berghe G. Tight blood-glucose control without early parenteral nutrition in the ICU. New England Journal of Medicine 2023;389:1180-1190

90. Mehta G, Lo B, Memarpour M, Chan A. Impact of diabetes on inpatient length of stay in adult mental health services in a community hospital setting: A retrospective cohort study. Canadian Journal of Diabetes 2022;46:678-682

91. McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care 2005;28:810-815

92. Baker EH, Janaway CH, Philips BJ, Brennan AL, Baines DL, Wood DM, Jones PW. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 2006;61:284-289

93. Noordzij PG, Boersma E, Schreiner F, Kertai MD, Feringa HH, Dunkelgrun M, Bax JJ, Klein J, Poldermans D. Increased preoperative glucose levels are associated with perioperative mortality in patients undergoing noncardiac, nonvascular surgery. European Journal of Endocrinology 2007;156:137-142

94. Martin ET, Kaye KS, Knott C, Nguyen H, Santarossa M, Evans R, Bertran E, Jaber L. Diabetes and risk of surgical site infection: A systematic review and meta-analysis. Infection Control & Hospital Epidemiology 2016;37:88-99

95. Pomposelli JJ, Baxter JK, Babineau TJ, Pomfret EA, Driscoll DF, Forse RA, Bistrian BR. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. Journal of Parenteral and Enteral Nutrition 1998;22:77-81

96. Ramos M, Khalpey Z, Lipsitz S, Steinberg J, Panizales MT, Zinner M, Rogers SO. Relationship of perioperative hyperglycemia and postoperative infections in patients who undergo general and vascular surgery. Annals of Surgery 2015;248:585-591

97. Sadoskas D, Suder NC, Wukich DK. Perioperative glycemic control and the effect on surgical site infections in diabetic patients undergoing foot and ankle surgery. Foot and Ankle Specialist 2016;9:24-30

98. Wallia A, Schmidt K, Oakes DJ, Pollack T, Welsh N, Kling-Colson S, Gupta S, Fulkerson C, Aleppo G, Parikh N, Levitsky J, Norvell JP, Rademaker A, Molitch ME. Glycemic control reduces infections in post-liver transplant patients: Results of a prospective, randomized study. Journal of Clinical Endocrinology & Metabolism 2017;102:451-459

99. Sheen YJ, Huang CC, Huang SC, Hung MD, Lin CH, Lee IT, Lin SY, Sheu WH. Implimentation of an electronic dashboard with a remote management system to improve glycemic management among hospitalized adults. Endocrine Practice 2020;26:179-191

100. Garg R, Schuman B, Bader A, Hurwitz S, Turchin A, Underwood P, Metzger C, Rein R, Lortie M. Effect of preoperative diabetes management on glycemic control and clinical outcomes after elective surgery. Annals of Surgery 2018;267:858-862

101. Gregory NS, Seley JJ, Ukena J, Shah S, Fred MR, Dargar SK, Mauer E, Kim RJ. Decreased rates of inpatient hypoglycemia following implementation of an automated tool in the electronic medical record for identifying root causes. Journal of Diabetes Science and Technology 2018;12:63-68

102. Pichardo-Lowden A, Umpierrez G, Lehman EB, Bolton MD, DeFlitch CJ, Chinchilli VM, Haidet PM. Clinical decision support to improve management of diabetes and dysglycemia in the hospital: a path to optimizing practice and outcomes. BMJ Open Diabetes Research & Care 2021;9:e001557

103. Wang YY, Hu SF, Ying HM, Chen L, Li HL, Tian F, Zhou ZF. Postoperative tight glycemic control significantly reduces postoperative infection rates in patients undergoing surgery: A meta-analysis. BMC Endocrine Disorders 2018;18:42

104. Vanhorebeek I, Gunst J, Van den Berghe G. Critical care management of stress-induced hyperglycemia. Current Diabetes Reports 2018;18:17

105. Gunst J, De Bruyn A, Van den Berghe G. Glucose control in the ICU. Current Opinion in Anesthesiology 2019;32:156-162

106. Dashora U, George S, Sampson M, Walden E. National guidelines have contributed to safer care for inpatients with diabetes. Diabetic Medicine 2019;36:124-126

107. Honarmand K, Sirimaturos M, Hirshberg EL, Bircher NG, Agus MS, Carpenter DL, Downs CR, Farrington EA, Freire AX, Grow A, Irving SY, Krinsley JS, Lanspa MJ, Long MT, Nagpal D, Preiser JC, Srinivasan V, Umpierrez GE, Jacobi J. Society of Critical Care Medicine guidelines on glycemic control for critically ill children and adults 2024. Critical Care Medicine 2024;52:e161-e181

108. Association AD. Diabetes care in the hospital: Standards of care in diabetes—2024. Diabetes Care 2023;47:S295-S306

109. Korytkowski MT, Muniyappa R, Antinori-Lent K, Donihi AC, Drincic AT, Hirsch IB, Luger A, McDonnell ME, Murad MH, Nielsen C, Pegg C, Rushakoff RJ, Santesso N, Umpierrez GE. Management of hyperglycemia in hospitalized adult patients in non-critical care settings: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism 2022;107:2101–2128

110. Lazar HL, McDonnell M, Chipkin SR, Furnary AP, Engelman RM, Sadhu AR, Bridges CR, Haan CK, Svedjeholm R, Taegtmeyer H, Shemin RJ. The Society of Thoracic Surgeons Practice Guideline Series: Blood glucose management during adult cardiac surgery. Annals of Thoracic Surgery 2009;87:663-669

111. Guidelines for the management of inpatient diabetes [article online], 2022. Available from <https://abcd.care/jbds-ip>.

112. End of life diabetes care [article online], 2021. Available from <https://www.diabetes.org.uk/professionals/position-statements-reports/diagnosis-ongoing-management-monitoring/end-of-life-care>.

113. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Bouillon R, Lauwers P. Intensive insulin therapy in critically ill patients. New England Journal of Medicine 2001;345:1359-1367

114. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R. Intensive insulin therapy in the medical ICU. New England Journal of Medicine 2006;354:449-461

115. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. New England Journal of Medicine 2008;358:125-139

116. De La Rosa G, Donado JH, Restrepo AH, Quintero AM, Gonzalez LG, Saldarriaga NE, Bedoya M, Toro JM, Velasquez JB, Valencia JC, Arango CM, Aleman PH, VAsquez EM, Chavarriaga JC, Yepes A, Pulido W, Cadavid CA. Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial. Critical Care 2008;12:R120

117. Preiser J-C, Brunkhorst F. Tight glucose control and hypoglycemia. Critical Care Medicine 2008;36:1391-1392

118. Marik PE. Tight glycemic control in acutely ill patients: low evidence of benefit, high evidence of harm! Intensive Care Medicine 2016;42:1475-1477

119. Umpierrez GE. Glucose control in the ICU. New England Journal of Medicine 2023;389:1234-1237

120. Krinsley JS, Rule P, Pappy L, Ahmed A, Huley-Rodrigues C, Prevedello D, Preiser J-C. The interaction of acute and chronic glycemia on the relationship of hyperglycemia, hypoglycemia, and glucose variability to mortality in the critically ill. Critical Care Medicine 2020;48:1744-1751

121. Malmberg KA, Efendic S, Ryden LE. Feasibility of insulin-glucose infusion in diabetic patients with acute myocardial infarction: A report from the multicenter trial: DIGAMI. Diabetes Care 1994;17:1007-1014

122. Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 2004;109:1497-1502

123. Gandhi GY, Nuttall GA, Abel MD, Mullany CJ, Schaff HV, O'Brien PC, Johnson MG, Williams AR, Cutshall SM, Mundy LM, Rizza RA, McMahon MM. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: A randomized trial. Annals of Internal Medicine 2007;146:233-243

124. Preiser J-C, Devos P, Ruiz-Santana S, Melot C, Annane D, Groeneveld J, Iapichino G, Leverve XM, Nitenberg G, Singer P, Wernerman J, Joannidis M, Stecher A, Chiolero R. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Medicine 2009;35:1738-1748

125. Agus MS, Steil GM, Wypij D, Costello JM, Laussen PC, Langer M, Alexander JL, Scoppettuolo LA, Pigula FA, Charpie JR, Ohye RG, Gaies MG. Tight glycemic control versus standard care after pediatric cardiac surgery. New England Journal of Medicine 2012;367:1208-1219

126. Agus MS, Wypij D, Hirshberg EL, Srinivasan V, Faustino EV, Luckett PM, Alexander JL, Asaro LA, Curley MA, Steil GM, Nadkarni VM. Tight glycemic control in critically ill children. New England Journal of Medicine 2017;376:729-741

127. Macrae D, Grieve R, Allen E, Sadique Z, Morris K, Pappachan J, Parslow R, Tasker RC, Elbourne D. A randomized trial of hyperglycemic control in pediatric intensive care. New England Journal of Medicine 2014;370:107-118

128. Kalfon P, Giraudeau B, Ichai C, Guerrini A, Brechot N, Cinotti R, Dequin P-F, Riu-Poulenc B, Montravers P, Annane D, Dupont H, Sorine M, Riou B. Tight computerized versus conventional glucose control in the ICU: a randomized controlled trial. Intensive Care Medicine 2014;40:171-181

129. Cinotti R, Ichai C, Orban JC, Kalfon P, Feuillet F, Roquilly A, Riou B, Blanloeil Y, Asehnoune K, Rozec B. Effects of tight computerized glucose control on neurological outcome in severely brain injured patients: A multicenter sub-group analysis of the randomized-controlled open-label CGAO-REA study. Critical Care 2014;18:498

130. Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Tokumaru T, Iiyama T, Sugimoto T, Kobayashi M, Yokoyama M, Hanazaki K. Intensive versus intermediate glucose control in surgical intensive care unit patients. Diabetes Care 2014;37:1516

131. Cardona S, Pasquel FJ, Fayfman M, Peng L, Jacobs S, Vellanki P, Weaver J, Halkos M, Guyton RA, Thourani VH, Umpierrez GE. Hospitalization costs and clinical outcomes in CABG patients treated with intensive insulin therapy. Journal of Diabetes and its Complications 2017;31:742-747

132. Dhatariya K. Should inpatient hyperglycaemia be treated? British Medical Journal 2013;346:f134

133. Phillips VL, Byrd AL, Adeel S, Peng L, Smiley DD, Umpierrez GE. A comparison of inpatient cost per day in general surgery patients with type 2 diabetes treated with basal-bolus versus sliding scale insulin regimens. PharmacoEconomics - Open 2017;1:109-115

134. Barmanray RD, Kyi M, Colman PG, Rowan L, Raviskanthan M, Collins L, Donaldson L, Montalto S, Tsan J, Sun E, Le M, Worth LJ, Thomson B, Fourlanos S. The specialist treatment of inpatients: Caring for diabetes in surgery (STOIC-D Surgery) trial: A randomized controlled trial of early intervention with an electronic specialist-led model of diabetes care. Diabetes Care 2024;47:948-955

135. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, Service FJ. Evaluation and management of adult hypoglycemic disorders: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism 2009;94:709-728

136. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R. Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care 2013;36:1384-1395

137. The hospital management of hypoglycaemia in adults with diabetes mellitus. Revised April 2021 [article online], 2021. Available from <https://abcd.care/resource/current/jbds-01-hospital-management-hypoglycaemia-adults-diabetes-mellitus>.

138. Krikorian A, Ismail-Beigi F, Moghissi ES. Comparisons of different insulin infusion protocols: a review of recent literature. Current Opinion in Clinical Nutrition & Metabolic Care 2010;13:198-204

139. Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, Puig A, Mejia R. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007;30:2181-2186

140. Rajendran R, Kerry C, Rayman G, on behalf of the MAGIC group. Temporal patterns of hypoglycaemia and burden of sulfonylurea-related hypoglycaemia in UK hospitals: a retrospective multicentre audit of hospitalised patients with diabetes. BMJ Open 2014;4

141. National Diabetes Inpatient Audit (NaDIA) - 2017 [article online], 2018. Available from <https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-inpatient-audit/national-diabetes-inpatient-audit-nadia-2017>.

142. Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: Risk factors and outcomes. Critical Care Medicine 2007;35:2262-2267

143. Kagansky N, Levy S, Rimon E. Hypoglycemia as a predictor of mortality in hospitalized elderly patients. Archives of Internal Medicine 2003;163:1825-1829

144. Lake A, Arthur A, Byrne C, Davenport K, Yamamoto JM, Murphy HR. The effect of hypoglycaemia during hospital admission on health-related outcomes for people with diabetes: a systematic review and meta-analysis. Diabetic Medicine 2019;36:1349-1359

145. Dendy J, Chockalingam V, Tirumalasetty N, Dornelles A, Blonde L, Bolton P, Meadows R, Andrews S. Identifying risk factors for severe hypoglycemia in hospitalized patients with diabetes. Endocrine Practice 2014;20:1051-1056

146. Smith WD, Winterstein AG, Johns T, Rosenberg E, Sauer BC. Causes of hyperglycemia and hypoglycemia in adult inpatients. American Journal of Health-System Pharmacy 2005;62:714-719

147. Maynard G, Lee J, Phillips G, Fink E, Renvall M. Improved inpatient use of basal insulin, reduced hypoglycemia, and improved glycemic control: Effect of structured subcutaneous insulin orders and an insulin management algorithm. Journal of Hospital Medicine 2009;4:3-15

148. Insulin safety. Reducing harm associated with the unsafe use of insulin products [article online], 2010. Available from <https://www.centreformedicinesoptimisation.co.uk/new-insulin-safety-guidance-issued-to-reduce-wrong-dosages/#:~:text=Learning%20from%20previous%20incidents%20like,insulin%20administration%20times%3B%20and%20putting>.

149. Griesdale DE, de Souza RJ, van Dam RM, Heyland DK, Cook DJ, Malhotra A, Dhaliwal R, Henderson WR, Chittock DR, Finfer S, Talmor D. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. Canadian Medical Association Journal 2009;180:821-827

150. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S. Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine 2010;363:1410-1418

151. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: A meta-analysis. JAMA 2008;300:933-944

152. Kosiborod M, Inzucchi S, Goyal A, Krumholz HM, Masoudi FA, Xiao L, Spertus JA. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA 2009;301:1556-1564

153. Arabi YM, Tamin HM, Rishu AH. Hypoglycemia with intensive insulin therapy in critically ill patients: Predisposing factors and association with mortality. Critical Care Medicine 2009;37:2536-2544

154. Vriesendorp TM, DeVries JH, van Santen S, Moeniralam HS, de Jong E, Roos YB, Schultz MJ, Rosendaal FR, Hoekstra JB. Evaluation of short-term consequences of hypoglycemia in an intensive care unit. Critical Care Medicine 2006;34:2714-2718

155. Krinsley JS, Schultz MJ, Spronk PE, Harmsen RE, van Braam Houckgeest F, van der Sluijs JP, Melot C, Preiser JC. Mild hypoglycemia is independently associated with increased mortality in the critically ill. Critical Care 2011;15:R173

156. National Diabetes Inpatient Audit (NaDIA) - 2016 [article online], 2017. Available from <http://www.content.digital.nhs.uk/catalogue/PUB23539>.

157. National Diabetes Inpatient Audit - Harms, 2019 [article online], 2020. Available from <https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-inpatient-audit---harms/national-diabetes-inpatient-audit---harms-2019/2019>.

158. Dashora U, Sampson M, Castro E, Stanisstreet D, Hillson R. The best hypoglycaemia avoidance initiative in the UK. British Journal of Diabetes 2017;17:74-77

159. Flanagan D, Avari P, Choudhary P, Lumb A, Misra S, Rayman G, Dhatariya K. Using technology to improve diabetes care in hospital: The challenge and the opportunity. Journal of Diabetes Science and Technology 2023;17:503-508

160. Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes—the 'dead in bed' syndrome revisited. Diabetologia 2009;52:42-45

161. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia. Diabetes Care 2003;26:1485-1489

162. Petersen KG, Schluter KJ, Kerp L. Regulation of serum potassium during insulin-induced hypoglycemia. Diabetes 1982;31:615-617

163. Razavi Nematollahi L, Kitabchi AE, Stentz FB, Wan JY, Larijani BA, Tehrani MM, Gozashti MH, Omidfar K, Taheri E. Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism - Clinical and Experimental 2009;58:443-448

164. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010;33:1389-1394

165. Boucai L, Southern WN, Zonszein J. Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities. American Journal of Medicine 2011;124:1028-1035

166. George JT, Warriner D, McGrane DJ, Rozario KS, Price HC, Wilmot EG, Kar P, Stratton IM, Jude EB, McKay GA. Lack of confidence among trainee doctors in the management of diabetes: the Trainees Own Perception of Delivery of Care (TOPDOC) Diabetes Study. QJM 2011;104:761-766

167. Horton WB, Law S, Darji M, Conaway MR, Akbashev MY, Kubiak NT, Kirby JL, Thigpen SC. A multicenter study evaluating perceptions and knowledge of inpatient glycemic control among resident physicians: analyzing themes to inform and improve care. Endocrine Practice 2019;25:1295-1303

168. Dei Cas A, Aldigeri R, Ridolfi V, Vazzana A, Ciardullo AV, Manicardi V, Sforza A, Tomasi F, Zavaroni D, Zavaroni I, Bonadonna RC. Efficacy of a training programme for the management of diabetes mellitus in the hospital: A randomized study (stage 2 of GOVEPAZ healthcare). Diabetes/Metabolism Research and Reviews 2023;39:e3708

169. Hommel I, Wollersheim H, Tack CJ, Mulder J, van Gurp PJ, Hulscher ME. Impact of a multifaceted strategy to improve perioperative diabetes care. Diabetic Medicine 2017;34:278-285

170. Brown G, Dodek P. Intravenous insulin nomogram improves blood glucose control in the critically ill. Critical Care Medicine 2001;29:1714-1719

171. Rea RS, Donihi AC, Bobeck M, Herout P, McKaveney TP, Kane-Gill SL, Korytkowski MT. Implementing an intravenous insulin infusion protocol in the intensive care unit. American Journal of Health-System Pharmacy 2007;64:385-395

172. George S, Dale J, Stanisstreet D. A guideline for the use of variable rate intravenous insulin infusion in medical inpatients. Diabetic Medicine 2015;32:706-713

173. Miller EE, Lalla M, Zaidi A, Elgash M, Zhao H, Rubin DJ. Eating and glycemic control among critically ill patients receiving continuous intravenous insulin. Endocrine Practice 2020;26:43-50

174. Salinas PD, Mendez CE. Glucose management technologies for the critically ill. Journal of Diabetes Science and Technology 2019;13:682-690

175. Ullal J, Aloi JA. Subcutaneous insulin dosing calculators for inpatient glucose control. Current Diabetes Reports 2019;19:120

176. Bouw JW, Campbell N, Hull MA, Juneja R, Guzman O, Overholser BR. A retrospective cohort study of a nurse-driven computerized insulin infusion program versus a paper-based protocol in critically ill patients. Diabetes Technology & Therapeutics 2012;14:125-130

177. Juneja R, Roudebush C, Kumar N, Macy A, Golas A, Wall D, Wolverton C, Nelson D, Carroll J, Flanders SJ. Utilization of a computerized intravenous insulin infusion program to control blood glucose in the intensive care unit. Diabetes Technology & Therapeutics 2007;9:232-240

178. Marvin MR, Inzucchi SE, Besterman BJ. Computerization of the Yale insulin infusion protocol and potential insights into causes of hypoglycemia with intravenous insulin. Diabetes Technology & Therapeutics 2013;15:246-252

179. Bouldin MG, Hong B, Setji T, Greenlee J, Cooper A, Thompson J, Capes K. Evaluation of the efficacy and safety of an eglycemic management system in a community hospital setting. Journal of Diabetes Science and Technology 2021;15:236-241

180. Goldberg PA, Siegel MD, Sherwin RS, Halickman JI, Lee M, Bailey VA, Lee SL, Dziura JD, Inzucchi SE. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care 2004;27:461-467

181. Boutin JM, Gauthier L. Insulin infusion therapy in critically ill patients. Canadian Journal of Diabetes 2014;38:144-150

182. DeSantis AJ, Schmeltz LR, Schmidt K, O'Shea-Mahler E, Rhee C, Wells A, Brandt S, Peterson S, Molitch ME. Inpatient management of hyperglycemia: The Northwestern experience. Endocrine Practice 2006;12:491-505

183. Davidson PC, Steed RD, Bode BW. Glucommander. A computer-directed intravenous insulin system shown to be safe, simple, and effective in 120,618 h of operation. Diabetes Care 2005;28:2418-2423

184. Newton CA, Smiley D, Bode BW, Kitabchi AE, Davidson PC, Jacobs S, Steed RD, Stentz F, Peng L, Mulligan P, Freire AX, Temponi A, Umpierrez GE. A comparison study of continuous insulin infusion protocols in the medical intensive care unit: Computer-guided vs. standard column-based algorithms. Journal of Hospital Medicine 2010;5:432-437

185. Leelarathna L, English SW, Thabit H, Caldwell K, Allen JM, Kumareswaran K, Wilinska ME, Nodale M, Mangat J, Evans ML, Burnstein R, Hovorka R. Feasibility of fully automated closed-loop glucose control using continuous subcutaneous glucose measurements in critical illness: a randomized controlled trial. Critical Care 2013;17:R159

186. Gómez Medina AM, Henao-Carrillo DC, Yepes C, Silva J, Gómez González JA, Cortes D, Robledo S, Mejía G, Rondon M. Glycemic control metrics in a cohort of hospitalized patients with type 1 diabetes using hybrid closed-loop and advanced hybrid closed-loop systems. Diabetes Research and Clinical Practice 2023;204:110897

187. Avari P, Lumb A, Flanagan D, Rayman G, Misra S, Choudhary P, Dhatariya K. Insulin pumps and hybrid close loop systems within hospital: A scoping review and practical guidance From the Joint British Diabetes Societies for Inpatient Care. Journal of Diabetes Science and Technology 2023;17:625-634

188. Migdal AL, Fortin-Leung C, Pasquel F, Wang H, Peng L, Umpierrez GE. Inpatient glycemic control with sliding scale insulin in noncritical patients with type 2 diabetes: Who can slide? Journal of Hospital Medicine 2021;16:462-468

189. Migdal AL, Idrees T, Umpierrez GE. Selecting insulin regimens for the management of non-ICU patients with type 2 diabetes. Journal of the Endocrine Society 2021;5

190. Hirsch IB. Sliding scale insulin--time to stop sliding. JAMA 2009;301:213-214

191. Umpierrez GE, Maynard G. Glycemic chaos (not glycemic control) still the rule for inpatient care. How do we stop the insanity? Journal of Hospital Medicine 2006;1:141-144

192. Swan E, Dhatariya K. Differential effects of intravenous and subcutaneous sliding scale insulin regimes used to improve blood glucose levels in a tertiary care setting. Practical Diabetes International 2009;26:2i

193. Vellanki P, Cardona S, Galindo RJ, Urrutia MA, Pasquel FJ, Davis GM, Fayfman M, Migdal A, Peng L, Umpierrez GE. Efficacy and safety of intensive versus nonintensive supplemental insulin with a basal-bolus insulin regimen in hospitalized patients with type 2 diabetes: A randomized clinical study. Diabetes Care 2022;45:2217-2223

194. King AB, Armstrong DU. Basal bolus dosing: A clinical experience. Current Diabetes Reviews 2005;1:215-220

195. Galindo RJ, Dhatariya K, Gomez-Peralta F, Umpierrez GE. Safety and efficacy of inpatient diabetes management with non‑insulin agents: an overview of international practices. Current Diabetes Reports 2022;22:237-246

196. Umpierrez GE, Hor T, Smiley D, Temponi A, Umpierrez D, Ceron M, Munoz C, Newton C, Peng L, Baldwin D. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. Journal of Clinical Endocrinology Metabolism 2009;94:564-569

197. Umpierrez GE, Smiley D, Hermayer K, Khan A, Olson DE, Newton C, Jacobs S, Rizzo M, Peng L, Reyes D, Pinzon I, Fereira ME, Hunt V, Gore A, Toyoshima MT, Fonseca VA. Randomized study comparing a basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: Basal plus trial. Diabetes Care 2013;36:2169-2174

198. Pietras S, Hanrahan P, Arnold L, Sternthal E, McDonnell M. State-of-the-art inpatient diabetes care: The evolution of an academic hospital. Endocrine Practice 2010;16:512-521

199. Clement S, Bowen-Wright H. Twenty-four hour action of insulin glargine (Lantus) may be too short for once-daily dosing: A case report. Diabetes Care 2002;25:1479-1147a

200. Rubin DJ, Rybin D, Doros G, McDonnell ME. Weight-based, insulin dose-related hypoglycemia in hospitalized patients with diabetes. Diabetes Care 2011;34:1723-1728

201. Koufakis T, Mustafa OG, Zebekakis P, Kotsa K. Oral antidiabetes agents for the management of inpatient hyperglycaemia: so far, yet so close. Diabetic Medicine 2020;37:1418-1426

202. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure. Diabetes Care 2004;27:256-263

203. Khalam A, Dilip C, Shinu C. Drug use evaluation of diabetes mellitus in hospitalized patients of a tertiary care referral hospital. Journal of Basic and Clinical Physiology and Pharmacology 2012;23:173-177

204. Willi SM, Kennedy A, Brant BP, Wallace P, Rogers NL, Garvey WT. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes. Diabetes Research & Clinical Practice 2002;58:87-96

205. Roberts A, James J, Dhatariya K, on behalf of the Joint british Diabetes Societies for Inpatient Care Group. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabetic Medicine 2018;35:1011-1017

206. Nirantharakumar K, Marshall T, Kennedy A, Hemming K, Coleman JJ. Hypoglycaemia is associated with increased length of stay and mortality in people with diabetes who are hospitalized. Diabetic Medicine 2012;29:e445-e448

207. Deusenberry CM, Coley KC, Korytkowski MT, Donihi AC. Hypoglycemia in hospitalized patients treated with sulfonylureas. Pharmacotherapy 2012;32:613-617

208. Stuart K, Adderley NJ, Marshall T, Rayman G, Sitch A, Manley S, Ghosh S, Toulis KA, Nirantharakumar K. Predicting inpatient hypoglycaemia in hospitalized patients with diabetes: a retrospective analysis of 9584 admissions with diabetes. Diabetic Medicine 2017;34:1385-1391

209. Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, Elasy TA, Griffin MR. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA 2014;311:2288-2296

210. Gerards MC, Venema GE, Patberg KW, Kross M, Potter van Loon BJ, Hageman IM, Snijders D, Brandjes DP, Hoekstra JB, Vriesendorp TM, Gerdes VE. Dapagliflozin for prednisone-induced hyperglycemia in acute exacerbation of chronic obstructive pulmonary disease. Diabetes, Obesity and Metabolism 2018;20:1306-1310

211. Empagliflozin to be investigated as a possible treatment for COVID-19 in the RECOVERY trial [article online], 2022. Available from <https://www.recoverytrial.net/news/empagliflozin-to-be-investigated-as-a-possible-treatment-for-covid-19-in-the-recovery-trial>.

212. Cohen B, Harris YT, Schulman-Rosenbaum R. SGLT2 inhibitors should be avoided for inpatient management of hyperglycemia. Endocrine Practice 2024;

213. Dhatariya K. Initiation and continuation of sodium-glucose cotransporter 2 inhibitors in hospital inpatients – ready for prime time? Diabetes Care 2022;45:2806-2807

214. Umpierrez GE, Gianchandani R, Smiley D, Wesorick DH, Newton C, Farrokhi F, Peng L, Lathkar-Pradhan S, Pasquel F. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: A pilot, randomized, controlled study. Diabetes Care 2013;36:3430-3435

215. Pasquel FJ, Gianchandani R, Rubin DJ, Dungan KM, Anzola I, Gomez PC, Peng L, Hodish I, Bodnar T, Wesorick D, Balakrishnan V, Osei K, Umpierrez GE. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes and Endocrinology 2017;5:125-133

216. Lorenzo-Gonzalez C, Atienza-Sanchez E, Reyes-Umpierrez D, Vellanki P, Davis GM, Pasquel FJ, Cardona S, Fayman M, Peng L, Umpierrez GE. Safety and efficacy of DDP-4 inhibitors for management of hospitalized general medicine and surgery patients with type 2 diabetes. Endocrine Practice 2020;26:722-728

217. Hulst AH, Plummer MP, Hollmann MW, DeVries JH, Preckel B, Deane AM, Hermanides J. Systematic review of incretin therapy during peri-operative and intensive care. Critical Care 2018;22:299

218. Kosiborod MN, Angermann CE, Collins SP, Teerlink JR, Ponikowski P, Biegus J, Comin-Colet J, Ferreira JP, Mentz RJ, Nassif ME, Psotka MA, Tromp J, Brueckmann M, Blatchford JP, Salsali A, Voors AA. Effects of empagliflozin on symptoms, physical limitations and quality of life in patients hospitalized for acute heart failure - results from the EMPULSE trial. Circulation 2022;146

219. Tamaki S, Yamada T, Watanabe T, Morita T, Furukawa Y, Kawasaki M, Kikuchi A, Kawai T, Seo M, Abe M, Nakamura J, Yamamoto K, Kayama K, Kawahira M, Tanabe K, Fujikawa K, Hata M, Fujita Y, Umayahara Y, Taniuchi S, Sanada S, Shintani A, Fukunami M. Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure. Circulation: Heart Failure 2021;14:e007048

220. Cunningham JW, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CS, Martinez F, Shah SJ, McGrath MM, O’Meara E, Wilderäng U, Lindholm D, Petersson M, Langkilde A, McMurray JJ, Solomon SD. Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. Journal of the American College of Cardiology 2022;80:1302-1310

221. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJ, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine 2022;28:568-574

222. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections [article online], 2022. Available from <https://www.fda.gov/Drugs/DrugSafety/ucm475463.htm>.

223. Guideline for perioperative care for people with diabetes mellitus undergoing elective and emergency surgery [article online], 2022. Available from <https://cpoc.org.uk/sites/cpoc/files/documents/2022-12/CPOC-Diabetes-Guideline-Updated2022.pdf>.

224. Rutter CL, Jones C, Dhatariya KK, James J, Irvine L, Wilson EC, Singh H, Walden E, Holland R, Harvey I, Bradley C, Sampson MJ. Determining in-patient diabetes treatment satisfaction in the UK—the DIPSat study. Diabetic Medicine 2013;30:731-738

225. Avari P, Lumb A, Flanagan D, Rayman G, Misra S, Dhatariya K, Choudhary P. Continuous glucose monitoring within hospital: A scoping review and summary of guidelines from the Joint British Diabetes Societies for Inpatient Care. Journal of Diabetes Science and Technology 2023;17:611-624

226. Rice MJ, Smith JL, Coursin DB. Glucose measurement in the ICU: Regulatory intersects reality. Critical Care Medicine 2017;45:741-743

227. Pilackas K, El-Oshar S, Carter C. Clinical reliability of point-of-care glucose testing in critically ill patients. Journal of Diabetes Science and Technology 2020;14:65-69

228. Misra S, Avari P, Lumb A, Flanagan D, Choudhary P, Rayman G, Dhatariya K. How can point-of-care technologies support in-hospital diabetes care? Journal of Diabetes Science and Technology 2023;17:509-516

229. Gomez AM, Umpierrez GE. Continuous glucose monitoring in insulin-treated patients in non-ICU settings. Journal of Diabetes Science and Technology 2014;8:930-936

230. Cardona S, Gomez PC, Vellanki P, Anzola I, Ramos C, Urrutia MA, Haw JS, Fayfman M, Wang H, Galindo RJ, Pasquel FJ, Umpierrez GE. Clinical characteristics and outcomes of symptomatic and asymptomatic hypoglycemia in hospitalized patients with diabetes. BMJ Open Diabetes Research & Care 2018;6:e000607

231. Galindo RJ, Aleppo G, Klonoff DC, Spanakis EK, Agarwal S, Vellanki P, Olson DE, Umpierrez GE, Davis GM, Pasquel FJ. Implementation of continuous glucose monitoring in the hospital: Emergent considerations for remote glucose monitoring during the COVID-19 pandemic. Journal of Diabetes Science and Technology 2020;14:822-832

232. Chow KW, Kelly DJ, Rieff MC, Skala PA, Kravets I, Charitou MM, Morley EJ, Gupta R, Miller JD. Outcomes and healthcare provider perceptions of real-time continuous glucose monitoring (rtCGM) in patients with diabetes and COVID-19 admitted to the ICU. Journal of Diabetes Science and Technology 2021;15:607-614

233. Klarskov CK, Kristensen PL. Experience from implementing telemetric in-hospital continuous glucose monitoring during the COVID-19 pandemic. Journal of Diabetes Science and Technology 2021;15:715-716

234. Faulds ER, Boutsicaris A, Sumner L, Jones L, McNett M, Smetana KS, May CC, Buschur E, Exline MC, Ringel MD, Dungan K. Use of continuous glucose monitor in critically ill COVID-19 patients requiring insulin infusion: An observational study. Journal of Clinical Endocrinology & Metabolism 2021;106:e4007-e4016

235. Perez-Guzman MC, Duggan E, Gibanica S, Cardona S, Corujo-Rodriguez A, Faloye A, Halkos M, Umpierrez GE, Peng L, Davis GM, Pasquel FJ. Continuous glucose monitoring in the operating room and cardiac intensive care unit. Diabetes Care 2021;44:e50-e52

236. Longo RR, Elias H, Khan M, Seley JJ. Use and accuracy of inpatient CGM during the COVID-19 pandemic: An observational study of general medicine and ICU patients. Journal of Diabetes Science and Technology 2022;16:1136-1143

237. Sweeney AT, Pena S, Sandeep J, Hernandez B, Chen Y, Breeze JL, Bulut A, Feghali K, Abdelrehim M, Abdelazeem M, Srivoleti P, Salvucci L, Cann SB, Norman C. Use of a continuous glucose monitoring system in high-risk hospitalized noncritically ill patients with diabetes after cardiac surgery and during their transition of care from the intensive care unit during COVID-19: A pilot study. Endocrine Practice 2022;28:615-621

238. Tingsarat W, Buranasupkajorn P, Khovidhunkit W, Boonchaya-anant P, Laichuthai N. The accuracy of continuous glucose monitoring in the medical intensive care unit. Journal of Diabetes Science and Technology 2022;16:1550-1554

239. Wernerman J, Desaive T, Finfer S, Foubert L, Furnary A, Holzinger U, Hovorka R, Joseph J, Kosiborod M, Krinsley J, Mesotten D, Nasraway S, Rooyackers O, Schultz M, Van Herpe T, Vigersky R, Preiser JC. Continuous glucose control in the ICU: report of a 2013 round table meeting. Critical Care 2014;18:226

240. Clinical Guideline: Guidelines for managing continuous subcutaneous insulin infusion (CSII, or 'insulin pump') therapy in hospitalised patients [article online], 2019. Available from <https://abcd.care/sites/abcd.care/files/CSII_DTN_FINAL%20210218.pdf>.

241. Wang M, Singh LG, Spanakis EK. Advancing the use of CGM devices in a non-ICU setting. Journal of Diabetes Science and Technology 2019;13:674-681

242. Tsur A, Cahn A, Israel M, Feldhamer I, Hammerman A, Pollack R. Impact of flash glucose monitoring on glucose control and hospitalization in type 1 diabetes: A nationwide cohort study. Diabetes/Metabolism Research and Reviews 2021;37:e3355

243. Spanakis EK, Urrutia A, Galindo RJ, Vellanki P, Migdal AL, Davis G, Fayfman M, Idrees T, Pasquel FJ, Coronado WZ, Albury B, Moreno E, Singh LG, Marcano I, Lizama S, Gothong C, Munir K, Chesney C, Maguire R, Scott WH, Perez-Guzman MC, Cardona S, Peng L, Umpierrez GE. Continuous glucose monitoring–guided insulin administration in hospitalized patients with diabetes: A randomized clinical trial. Diabetes Care 2022;45:2369-2375

244. Pasquel FJ, Lansang MC, Dhatariya K, Umpierrez GE. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes & Endocrinology 2021;9:174-188

245. Singh LG, Satyarengga M, Marcano I, Scott WH, Pinault LF, Feng Z, Sorkin JD, Umpierrez GE, Spanakis EK. Reducing inpatient hypoglycemia in the general wards using real-time continuous glucose monitoring: The glucose telemetry system, a randomized clinical trial. Diabetes Care 2020;43:2736-2743

246. Davis GM, Galindo RJ, Migdal AL, Umpierrez GE. Diabetes technology in the inpatient setting for management of hyperglycemia. Endocrinology and Metabolism Clinics 2020;49:79-93

247. Wang G, Liu X, Ying Z, Yang G, Chen Z, Liu Z, Zhang M, Yan H, Lu Y, Gao Y, Xue K, Li X, Chen Y. Optimized glycemic control of type 2 diabetes with reinforcement learning: a proof-of-concept trial. Nature Medicine 2023;29:2633-2642

248. Using technology to support diabetes care in hospital: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS-IP) Group and Diabetes Technology Network (DTN) [article online], 2024. Available from <https://abcd.care/resource/current/jbds-20-using-technology-support-diabetes-care-hospital>.

249. Lumb A, Misra S, Rayman G, Avari P, Flanagan D, Choudhary P, Dhatariya K. Variation in the current use of technology to support diabetes management in UK hospitals: Results of a survey of health care professionals. Journal of Diabetes Science and Technology 2023;17:733-741

250. McMahon MM, Nystrom E, Braunschweig C, Miles J, Compher C, Nutrition ASfPaE. A.S.P.E.N. clinical guidelines: Nutrition support of adult patients with hyperglycemia. Journal of Parenteral and Enteral Nutrition 2013;37:23-36

251. Lobo DN, Gianotti L, Adiamah A, Barazzoni R, Deutz NE, Dhatariya K, Greenhaff PL, Hiesmayr M, Hjort Jakobsen D, Klek S, Krznaric Z, Ljungqvist O, McMillan DC, Rollins KE, Panisic Sekeljic M, Skipworth RJ, Stanga Z, Stockley A, Stockley R, Weimann A. Perioperative nutrition: Recommendations from the ESPEN expert group. Clinical Nutrition 2020;39:3211-3227

252. JBDS guideline on the glycaemic management during the inpatient enteral feeding of stroke patients with diabetes [article online], 2012. Available from <http://www.diabetologists-abcd.org.uk/JBDS/JBDS_IP_Enteral_Feeding_Stroke.pdf>.

253. Flanagan D, Lake AK, Green M, Roberts A, Dhatariya K, on behalf of the Joint British Diabetes Societies for Inpatient Care Group. A UK national survey of enteral feed use in people with diabetes 2022. Diabetic Medicine 2023;n/a:e15216

254. McMahon MM, Rizza RA. Nutrition support in hospitalized patients with diabetes mellitus. Mayo Clinic Proceedings 1996;71:587-594

255. Singer P, Blaser AR, Berger MM, Alhazzani W, Calder PC, Casaer MP, Hiesmayr M, Mayer K, Montejo JC, Pichard C, Preiser J-C, van Zanten AR, Oczkowski S, Szczeklik W, Bischoff SC. ESPEN guideline on clinical nutrition in the intensive care unit. Clinical Nutrition 2019;38:48-79

256. Preiser J-C, Arabi YM, Berger MM, Casaer M, McClave S, Montejo-González JC, Peake S, Reintam Blaser A, Van den Berghe G, van Zanten A, Wernerman J, Wischmeyer P. A guide to enteral nutrition in intensive care units: 10 expert tips for the daily practice. Critical Care 2021;25:424

257. Via MA, Mechanick JI. Inpatient enteral and parental nutrition for patients with diabetes. Current Diabetes Reports 2011;11:99-105

258. Elia M, Ceriello A, Laube H, Sinclair AJ, Engfer M, Stratton RJ. Enteral nutritional support and use of diabetes-specific formulas for patients with diabetes: A systematic review and meta-analysis. Diabetes Care 2005;28:2267-2279

259. Glycaemic management during the inpatient enteral feeding of stroke patients with diabetes [article online], 2024. Available from <https://abcd.care/resource/jbds-05-glycaemic-management-during-inpatient-enteral-feeding-stroke-patients-diabetes>.

260. Narwani V, Swafe L, Stavraka C, Dhatariya K. How frequently are bedside glucose levels measured in hospital inpatients on glucocorticoids? Clinical Medicine 2014;14:327-328

261. Sudlow A, O'Connor HM, Narwani V, Swafe L, Dhatariya K. Assessing the prevalence of dexamethasone use in patients undergoing surgery, and subsequent glucose measurements: a retrospective cohort study. Practical Diabetes 2017;34:117-121

262. Limbachia V, Nunney I, Page DJ, Barton HA, Patel LK, Thomason GN, Green SL, Lewis KF, Dhatariya K. The effect of different types of oral or intravenous corticosteroids on capillary blood glucose levels in hospitalized inpatients with and without diabetes. Clinical Therapeutics 2024;46

263. Limbachia V, Nunney I, Page DJ, Barton HA, Patel LK, Thomason GN, Green SL, Lewis KF, Dhatariya K. The effect of different types of oral or intravenous corticosteroids on capillary blood glucose levels in hospitalized inpatients with and without diabetes. Clinical Therapeutics 2024;46:e59-363

264. Flanagan D, Dhatariya K, Kilvert A, on behalf of the Joint British Diabetes Societies for Inpatient Care (JBDS-IP) Group. Self-management of diabetes in hospital: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabetic Medicine 2018;35:992-996

265. Yatabe T, Yamazaki R, Kitagawa H, Okabayashi T, Yamashita K, Hanazaki K, Yokoama M. The evaluation of the ability of closed-loop glycemic control device to maintain the blood glucose concentration in intensive care unit patients. Critical Care Medicine 2011;39:575-578

266. Levitt DL, Spanakis EK, Ryan KA, Silver KD. Insulin pump and continuous glucose monitor initiation in hospitalized patients with type 2 diabetes mellitus. Diabetes Technology & Therapeutics 2018;20:32-38

267. Pelkey MN, Boyle ME, Long A, Castro JC, Cook CB, Thompson B. Hybrid closed loop insulin pump technology can be safely used In the inpatient setting. Endocrine Practice 2023;29:24-28

268. Bally L, Thabit H, Hartnell S, Andereggen E, Ruan Y, Wilinska ME, Evans ML, Wertli MM, Coll AP, Stettler C, Hovorka R. Closed-loop insulin delivery for glycemic control in noncritical care. New England Journal of Medicine 2018;379:547-556

269. Thabit H, Hartnell S, Allen JM, Lake A, Wilinska ME, Ruan Y, Evans ML, Coll AP, Hovorka R. Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial. Lancet Diabetes & Endocrinology 2020;5:117-124

270. Boughton CK, Bally L, Martignoni F, Hartnell S, Herzig D, Vogt A, Wertli MM, Wilinska ME, Evans ML, Coll AP, Stettler C, Hovorka R. Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial. Lancet Diabetes & Endocrinology 2019;7:368-377

271. Stewart ZA, Wilinska ME, Hartnell S, Temple RC, Rayman G, Stanley KP, Simmons D, Law GR, Scott EM, Hovorka R, Murphy HR. Closed-loop insulin delivery during pregnancy in women with type 1 diabetes. New England Journal of Medicine 2016;375:644-654